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Familial hypercholesterolemia (FH) is a common genetic cause of premature
cardiovascular disease (CVD). The reported prevalence rates for both heterozygous FH
(HeFH) and homozygous FH (HoFH) vary significantly, and this can be attributed, at
least in part, to the variable diagnostic criteria used across different populations. Due
to lack of consistent data, new global registries and unified guidelines are being formed,
which are expected to advance current knowledge and improve the care of FH patients.
This review presents a comprehensive overview of the pathophysiology, epidemiology,
manifestations, and pharmacological treatment of FH, whilst summarizing the up-to-date
relevant recommendations and guidelines. Ongoing research in FH seems promising and
novel therapies are expected to be introduced in clinical practice in order to compliment
or even substitute current treatment options, aiming for better lipid-lowering effects, fewer
side effects, and improved clinical outcomes.
Keywords: familial hypercholesterolemia (FH), heterozygous FH (HeFH), homozygous FH (HoFH), atherosclerotic
cardiovascular disease (ASCVD), low density lipoprotein (LDL), statins, proprotein convertase subtilisin/kexin type
9 inhibitors (PCSK9 inhibitors)
INTRODUCTION
During the past decades, significant advances have been made in the prevention and treatment of
atherosclerotic cardiovascular disease (ASCVD). Chronic exposure to high circulating cholesterol
levels is a key atherogenic risk factor which characterizes familial hypercholesterolemia (FH) (Ito
and Watts, 2015; Catapano et al., 2016), a genetic disease closely related with premature ASCVD
and high mortality rates (Ito and Watts, 2015).
FH is a genetic disorder of the lipoprotein metabolism and constitutes one of the most
common inherited metabolic disorders (Goldberg et al., 2011; Vickery et al., 2014). The
underlying cause of FH is a genetic defect either of the low density lipoprotein receptor (LDLR)
or of the proteins that regulate its metabolism, resulting in abnormally low uptake of low
density lipoprotein (LDL) by the liver. Consequently, this leads to cholesterol accumulation
Abbreviations:ASCVD, Atherosclerotic cardiovascular disease; FH, Familial hypercholesterolemia; HeFH, heterozygous FH;
HoFH, homozygous FH; NLA, National lipid association; PCSK9, proprotein convertase subtilisin/kexin type 9 inhibitors;
MEDPED, Make early diagnosis to prevent early death; MACE, Major adverse cardiac events.
Mytilinaiou et al. FH: Diagnosis and Management
in the circulation, which explains the associated high CVD risk
(Hartgers et al., 2015; Ito and Watts, 2015; Baum et al., 2016).
Of note, distinction between the maternal or paternal type of
inheritance does not have an impact on the FH phenotype
(Narverud et al., 2015).
FH presents with significant heterogeneity, depending on the
specific gene defect and the variable degree of the accompanying
high plasma LDL levels (Hovingh et al., 2013). As such,
inheritance of only one mutant allele results in heterozygous
familial hypercholesterolemia (HeFH), with reduced LDL
clearance (2/3 of the normal rate) which leads to a 2- to 3-
fold increase in circulating LDL (5–10mmol/l; 200–400mg/dl)
(Parihar et al., 2012; Hovingh et al., 2013). The phenotypic
expression of HeFH is particularly distributed between the third
and sixth decade of life (Parihar et al., 2012). On the other
hand, a genotype with both mutant alleles, either with the
same (true homozygosity) mutation (pathogenic variant) or
with different pathogenic variants (compound heterozygosity),
translates to total absence or total defect of the LDLR (Ito and
Watts, 2015). This leads to worse prognosis due to diminished
LDLR functionality (European Association for Cardiovascular
Prevention and Rehabilitation et al., 2011; Bouhairie and
Goldberg, 2015), which depends crucially upon the levels of
circulating LDL and not on the specific mutation (Hovingh et al.,
2013).
Notably, in homozygous familial hypercholesterolemia
(HoFH) patients the LDL clearance reaches only 1/3 of the
normal rate according to previously published data, resulting
in exponentially increased LDL plasma levels (Parihar et al.,
2012). Thus, HoFH results in markedly high cholesterol levels
(3- to 6-fold higher than normal; >15.5mmol/l; >600mg/dl;
Hovingh et al., 2013; Ito and Watts, 2015). This leads to CVD
due to atherosclerotic plaques and stenosis [e.g., coronary artery
disease (CAD), calcifications in the aortic root and ascending
aorta, aortic regurgitation, and even CVD death] usually first
presenting during the first two decades of life (Kolansky et al.,
2008; Hovingh et al., 2013; Ito and Watts, 2015; Raal et al.,
2016b). After assessing and following up 39 HoFH patients,
among whom there were 22 children ≤16 y.o., Kolansky et al.
(2008) highlighted the presence of CVD even in the first decade
of their lives and due to the progression of their CVD pathology
in their teenage years, it is suggested that CVD risk screening
could start early in childhood (Kolansky et al., 2008). It is
important to also mention that more recent data present the
great phenotypic heterogeneity regarding LDL levels (Foody
and Vishwanath, 2016; Sanchez-Hernandez et al., 2016) and
ASCVD, according to the type of the pathogenic variant in
HoFH (e.g., true homozygotes vs. compound heterozygotes,
gene involved, and null vs. defective alleles), hence suggesting
that LDL clearance is probably related to the specific genotype
(Sanchez-Hernandez et al., 2016).
This genetic derangement of the normal lipidemic/metabolic
profile is well-known to induce atherogenesis, and, consequently,
premature CVD (European Association for Cardiovascular
Prevention and Rehabilitation et al., 2011; Nordestgaard et al.,
2013). Not surprisingly, a significant proportion of the CVD
events before the age of 45 is attributed to FH (Bouhairie and
Goldberg, 2015). Indeed, the estimated risk of premature CVD
in FH patients is 20-fold higher compared to that of the general
population (Hovingh et al., 2013), and the lifetime CVD events
are 3.9 timesmore likely than for patients with similar risk factors
without FH (Villa et al., 2017). Of note, a recent multicenter
study in Japanese patients (an ethnic population with low CVD
incidence) reported that the prevalence of definite HeFH was
5.7% in patients with acute coronary syndrome (Ohmura et al.,
2017). It should be also highlighted that such CAD events tend
to present even sooner and most often in male patients (Neil
et al., 2008). Overall, FH has been particularly associated with
myocardial infarction (MI), angina pectoris, as well as peripheral
arterial disease (PAD) and, hence, with increased mortality
and disability-adjusted life years (Hutter et al., 2004; European
Association for Cardiovascular Prevention and Rehabilitation
et al., 2011; Nordestgaard et al., 2013; Perez de Isla et al., 2016).
Apart from the LDLR, other molecules like members of
the scavenger receptor superfamily (SR-A1, SR-B1, SR-D1,
SRE1, SR-F1, SR-H1&2) and the Lectin-like oxLDL receptor-
1 (LOX1) are implicated in atherosclerosis through activation
of different intracellular pathways, downstream of their binding
with acetylated and/or oxidized LDL (Zani et al., 2015; Paquette
et al., 2017b). It is now known that the concomitant presence
of pathogenic variants in the oxidized-LDL receptor 1 (OLR1)
gene in HeFH patients indicates higher CAD risk (Paquette
et al., 2017b). Additionally, the recent discovery of a different
metabolic pathway in endothelial cells, involving LDL uptake
and transcytosis into endothelial cells through the acting-like
kinase 1 (ALK1), in the absence of LDLR, has drawn more
attention toward LDLR-independent mechanisms in order to
more successfully address LDL accumulation and atherosclerosis
(Kraehling et al., 2016).
Despite its relatively high prevalence and the well-established
impact on CVD, FH is often underdiagnosed in clinical
practice (deGoma et al., 2016; Knickelbine et al., 2016; Ershova
et al., 2017). Moreover, although a relatively broad arsenal of
therapeutic options is available, FH still remains a frequently
under-treated condition (Benn et al., 2012; Lahtinen et al., 2015;
Knickelbine et al., 2016; Ershova et al., 2017; Zamora et al., 2017).
Taking into account the CVD-related burden on public health
and the related health care expenditures (annual related costs that
reach 192 billion Euro in the EU), it becomes evident that the
effective management of FH poses a great challenge in clinical
practice (European Association for Cardiovascular Prevention
and Rehabilitation et al., 2011; Goldberg et al., 2011; Ito and
Watts, 2015).
FH GENETICS
The genetic diversity of FH results in significant phenotypic
variability, rendering the diagnosis challenging, while it further
highlights the need for individualized treatment strategies (Foody
and Vishwanath, 2016). It is now clear that the underlying
pathogenic mechanism in FH is the defective LDL clearance
(Turgeon et al., 2016). The monogenic dominant inherited
form is the most common type, comprising of three different
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pathogenic variants, namely of the LDLR gene, apolipoprotein
B (ApoB), and pro-protein convertase subtilisin/kexin type
9 (PCSK9) (Hovingh et al., 2013; Turgeon et al., 2016).
Furthermore, recent studies report pathogenic variants in the
ApoE and Stap1 genes as extremely rare causes of autosomal
dominant FH (Defesche et al., 2017; Pirillo et al., 2017). In
addition to the dominant form of inheritance, FH may also
present due to a very rare autosomal recessive form caused by
a mutation in the LDLR adaptor protein 1 (LDLRAP1) gene
(Garcia et al., 2001).
LDLR is the main cell membrane receptor for LDL in
hepatocytes and its role is to remove LDL from the circulation
through internalization of this ligand-receptor complex (Huff
et al., 2014; Bouhairie and Goldberg, 2015; Turgeon et al., 2016).
These receptors are recycled many times before specific enzymes
(e.g., PCSK9 and IDOL) lead to their lysosomal degradation
(Huff et al., 2014). To date, according to the British Heart
Foundation (BHF) database, 1741 allelic variations of the LDLR
have been registered, with 73.5% of them being substitutions
(www.ucl.ac.uk/ldlr/LOVDv.1.1.0/). The classification (Class 1
through 5) of the different pathogenic variants includes:
completely absent receptors, blocked transport to the Golgi
apparatus, dysfunctional receptors or defective internalization,
and recycling (Hartgers et al., 2015).
The primary screening target for FH is the LDLR pathogenic
variants, accounting for more than 90% of the FH cases (Hartgers
et al., 2015). In the remaining cases, the second in prevalence
gene mutation involves ApoB (2–5% of cases) (Patel et al.,
2015), an apolipoprotein that is found on each LDL particle and
is responsible for the specific ligand-receptor binding and the
subsequent clearance of LDL from the circulation (Walldius and
Jungner, 2004). In these cases, the mutant apolipoprotein B-100
(specific for LDL, IDL, and VLDL) impairs the binding of the
ApoB-containing particles by the LDLR in the liver, resulting
in their accumulation in the systemic circulation which further
triggers atherogenesis (Walldius and Jungner, 2004; Patel et al.,
2015).
PCSK9 constitutes the third gene implicated in LDL
metabolism in FH, mediating the LDLR degradation in
lysosomes. Thus, PCSK9 pathogenic variants with either gain-
or loss-of-function directly affect the LDL availability in
the bloodstream. Indeed, gain-of-function pathogenic variants,
which result in increased LDLR degradation, account for <1%
of the FH cases (Patel et al., 2015).
Finally, the aforementioned rare autosomal recessive type of
FH is associated with the loss-of-function pathogenic variants
of the LDLRAP1. This protein is involved in clathrin-dependent
internalization/endocytosis of the LDLR, hence, these pathogenic
variants also attenuate the LDL clearance from the circulation
(Garcia et al., 2001; Rader et al., 2003).
FH EPIDEMIOLOGY
Current epidemiological data on the prevalence of HeFH vary
according to the screened population (Goldstein et al., 1973;
Mabuchi et al., 1977; Moorjani et al., 1989; Seftel et al., 1989;
TABLE 1 | Reported prevalence rates of heterozygous familial
hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia
(HoFH) in various countries/ethnic populations.
Country/Ethnic population [References] HeFH prevalence rate
United States 1973 (Goldstein et al., 1973) 1:500
United States 2016, SEARCH Study (Safarova
et al., 2016)
1:310
United States 2016, NHANES Study (de Ferranti
et al., 2016)
1:250
Québécois French Canadians (Moorjani et al., 1989) 1:270
Tunisia (Slimane et al., 1993) 1:165
Finnish North Karelia (Vuorio et al., 1997) 1:441
Hungary (Kalina et al., 2001) 1:538
United Kingdom (Austin et al., 2004) 1:623
Denmark (Benn et al., 2012) 1:137
Catalan (Zamora et al., 2017) 1:192
Australia (Pang et al., 2016) 1:267
Japan (Mabuchi et al., 1977) 1:900
China (Zhou and Zhao, 2016) 1:212–1:357
Lebanon (Austin et al., 2004) 1:85
South Africa/Afrikaners (Steyn et al., 1996) 1:72
Ashkenazi Jews (Seftel et al., 1989) 1:67
West Siberian (Russian Federation) (Ershova et al.,
2017)
1:108
Country/Ethnic population [References] HoFH prevalence rate
Netherlands (Dutch) (Sjouke et al., 2015) 1:300,000
Catalan (Zamora et al., 2017) 1:425,774
Spain (Sanchez-Hernandez et al., 2016) 1:450,000
Québécois French Canadians (Moorjani et al., 1989) 1:275,000
Slimane et al., 1993; Steyn et al., 1996; Vuorio et al., 1997; Kalina
et al., 2001; Austin et al., 2004; Benn et al., 2012; Nordestgaard
et al., 2013; de Ferranti et al., 2016; Pang et al., 2016; Safarova
et al., 2016; Zhou and Zhao, 2016; Casula et al., 2017; Ershova
et al., 2017; Zamora et al., 2017). As such, previous data have
reported a HeFH prevalence of 1:500 in Caucasian MI survivors
(Goldstein et al., 1973), while more recent studies showed rates
of 1:137 in an unselected Danish population sample (Benn et al.,
2012), and 1:192 in a Catalan database sample (Zamora et al.,
2017). Similarly, the SEARCH Study reported a HeFH prevalence
rate of 1:310 in a US population applying an e-phenotyping
algorithm on electronic health care records (Safarova et al., 2016),
whilst the 2016 US NHANES study reported a rate of 1:250
(de Ferranti et al., 2016). It should be noted that the different
prevalence rates in various ethnic populations are also partly
attributed to the lack of uniformity in the criteria used for FH
diagnosis, the genotypic/phenotypic FH variations which might
make the correct diagnosis challenging, as well as the different
awareness and education/training worldwide (Goldberg et al.,
2011; Benn et al., 2012; EAS Familial Hypercholesterolaemia
Studies Collaboration et al., 2016; Foody and Vishwanath, 2016;
Zhou and Zhao, 2016; Casula et al., 2017). Table 1 summarizes
the available data on the reported HeFH prevalence rates in
different countries/ethnic populations.
Moreover, prevalence rates of 1:1,000,000 have been
previously reported for HoFH (Nordestgaard et al., 2013).
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However, more recently, Sjouke et al. suggested a higher
prevalence of approximately 1:300,000 based on a Dutch
population sample (Sjouke et al., 2015), while a database analysis
of Catalan patients reported a rate of 1:425,774 (Zamora et al.,
2017). Similarly, another Spanish study estimated the HoFH
prevalence at 1:450,000 (Sanchez-Hernandez et al., 2016), while
the reported HoFH prevalence in Québécois French Canadians
was 1:275,000 (Moorjani et al., 1989) (Table 1). Considering
that <1% of the FH population is detected in most countries
worldwide and that CVD constitutes the first cause of death
globally, such data on the FH prevalence appear not only
reasonable, but further highlight the possibility that the actual
undetected FH prevalence is even higher (Nordestgaard et al.,
2013).
CLINICAL FINDINGS IN FH
The most common clinical findings in FH patients include
tendon xanthomas, xanthelasmas (seen under the age of 25), and
the corneal arcus (under the age of 45) (Bouhairie and Goldberg,
2015), with the former being considered specific and diagnostic
for FH (European Association for Cardiovascular Prevention and
Rehabilitation et al., 2011). However, not all FH patients present
with clinical signs (Bouhairie and Goldberg, 2015).
These findings are considered related to the storage of
circulating cholesterol inside macrophages of the extracellular
matrix inside the tendons or the skin (Kim and Han, 2013;
Soslowsky and Fryhofer, 2016). The Achilles tendon and the
extensor tendons of the dorsum of the hands constitute the most
common sites for tendon xanthomas; however, xanthomas may
also involve the feet, elbows and antecubital fossae, knees, and
buttocks (European Association for Cardiovascular Prevention
and Rehabilitation et al., 2011; Kim and Han, 2013; Soslowsky
and Fryhofer, 2016). Notably, tendon xanthomas can progress
from thickening to tendon deposits, leading to significant
changes in tendon biomechanics (Kim and Han, 2013; Soslowsky
and Fryhofer, 2016).
It is also important to note that, although tendon xanthomas
are specific/diagnostic for FH, lipid profile assessments should
always be part of the diagnostic approach since there is also
the rare possibility of diseases with either normal cholesterol
(e.g., cases of cerebrotendinous xanthomatosis) (Parente et al.,
2016), or normal/high cholesterol (e.g., sitosterolemia), which is
responding extremely well to low cholesterol diet and bile acid
sequestrants and it could be perhaps suspected in patients with
poor response to statins, especially if these also fit the whole
clinical picture (Yoo, 2016).
Xanthelasmas and arcus cornealis are the two features/signs
that may be noted from the examination of the ocular area
and eyes in FH patients. The former represents deposition of
cholesterol around the eyelids, usually near the inner canthus.
Further examination of the patient’s cornea may reveal also a
brighter zone around the rim, i.e., the arcus cornealis (Kim
and Han, 2013). These findings further reflect the degree of the
underlying atherosclerotic damage throughout the vasculature,
and thus, their presence on clinical examination should alert
clinicians and prompt the early diagnosis and treatment of FH
(Hovingh et al., 2013; Hartgers et al., 2015; Ito and Watts, 2015).
FH DIAGNOSIS: DIAGNOSTIC CRITERIA
AND APPROACH
FH still remains greatly underdiagnosed (Hovingh et al., 2013),
despite the fact that there are several diagnostic criteria/systems
which can be reliably applied in everyday clinical practice once an
alarming family/personal history or suspicious clinical sign(s) are
noted. Such systems must be applied promptly in order to lead to
early diagnosis and treatment of FH patients, preventing disease
progression and ASCVD. Hence, increased awareness is needed
among clinicians, especially in primary care, in order to tackle
this problem in routine practice.
Notably, the existing diagnostic systems (mostly scoring
algorithms) for FH entail slightly different criteria which
vary on the proposed biochemical values/cut offs, but their
prediction value is relatively similar (European Association
for Cardiovascular Prevention and Rehabilitation et al., 2011;
Hartgers et al., 2015). According to the European 2016 guidelines,
FH should be suspected when patients present with premature
CVD (men <55 y.o. and women <60 y.o.), have a family
history of premature CVD, have a family history of tendon
xanthomas, and when their LDL is >5mmol/l (190mg/dl), or
LDL>4mmol/l (150mg/dl) in children (Catapano et al., 2016).
Currently, the main diagnostic systems for FH include: the
US Make Early Diagnosis to Prevent Early Death (MEDPED)
and WHO criteria (Table 2); the UK Simon Broome system
(UK FH Register criteria) (Table 3); the Dutch Lipid Network
Criteria (Table 4); the National Lipid Association (NLA) expert
panel recommendations (Table 5); as well as the Japanese
FH diagnostic criteria (Table 6) (European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011;
Harada-Shiba et al., 2012b; Hartgers et al., 2015; Turgeon et al.,
2016). Of these, the Simon Broome criteria indicate a possible
or definite diagnosis, while the Dutch Lipid Network criteria, as
well as the US MEDPED andWHO system calculate a diagnostic
score (Health Quality Ontario, 2007; European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011).
The NLA criteria may be useful for FH detection in childhood,
and clinicians should keep in mind that children with LDL levels
≥4.1mmol/l (≥160mg/dl) are most probably diagnosed with FH
(Ito and Watts, 2015). In order to avoid false negative results
due to high HDL obscuring LDL levels in HeFH, screening
should start after the first 6 weeks of life. Notably, high LDL
levels are expected throughout childhood and adulthood, with
the exception of pubertal years, when the growth spurt takes
place (European Association for Cardiovascular Prevention and
Rehabilitation et al., 2011).
Another important parameter in the diagnosis of FH is
the family history. As the index patient may present for
investigations before any other family member(s) develop CVD
or with unknown/unclear family CVD history, this factor can be
frequently underestimated. This also constitutes a problem when
dealing with populations/patient groups with already high CVD
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TABLE 2 | MEDPED and WHO criteria for FH diagnosis.
US MEDPED and WHO CRITERIA for
FH diagnosis
SCORE
FAMILY HISTORY
First degree relative with premature CAD
and/or LDL >95th centile
1
First degree relative with tendon
xanthomas and/or children <18 with LDL
>95th centile
2
CLINICAL HISTORY
Premature CAD 2
Premature cerebral/peripheral vascular
disease
1
PHYSICAL EXAMINATION
Tendon xanthomas 6
Arcus cornealis <45 y.o 4
LDL
>8.5mmol/l (>330mg/dl) 8
6.5–8.4mmol/l (250–329mg/dl) 5
5–6.4mmol/l (190–249mg/dl) 3
4–4.9mmol/l (155–189mg/dl) 1
DIAGNOSIS ACCORDING TO OVERALL SCORE
Definite >8
Probable 6–8
Possible 3–5
Unlikely <3
FH, Familial hypercholesterolemia; MEDPED, Make early diagnosis to prevent early death;
WHO, World health organization; LDL, Low density lipoprotein; CAD, Coronary artery
disease.
prevalence (European Association for Cardiovascular Prevention
and Rehabilitation et al., 2011).
Finally, FH diagnosis could be confirmed by genetic testing
(European Association for Cardiovascular Prevention and
Rehabilitation et al., 2011). Investigation of the monogenic form
of FH includes testing for pathogenic variants in the genes for
LDLR, ApoB, PCSK9 (related with the autosomal dominant
type), and LDLRAP1 (autosomal recessive form) (Harada-Shiba
et al., 2012a; Ito and Watts, 2015). Till recently, with the
different detection techniques used, 30% of patients with a
definite FH diagnosis were suspected to be missed due to the high
variability of the underlying pathogenic variants (Watts et al.,
2015). Next generation sequencing (NGS) seems a promising
technique as far as detection rates are concerned (Bell andWatts,
2016) and it is now the method of choice for FH detection
in the UK, recommended by NICE, as it is proven to be
cost-effective (https://www.nice.org.uk/guidance/cg71/evidence/
surveillance-review-decision-june-2015-pdf-2361738349).
Through simultaneous screening of multiple genes this
technique can identify known and novel causative pathogenic
variants for FH, helping scientists to know more about
FH (Hartgers et al., 2015; Watts et al., 2015). This would
be particularly useful for understudied populations and
should be performed by appropriate laboratories in order
to classify the findings as benign/pathogenic/of unknown
significance (Hartgers et al., 2015; Watts et al., 2015) and
TABLE 3 | Simon Broome criteria for diagnosis of familial hypercholesterolemia.
Simon Broome criteria for FH diagnosis
1. In adults: TC >7.5mmol/L (or, when
available, LDL >4.9mmol/L) and in
pediatric patients: TC >6.7mmol/L, or
LDL >4.0mmol/L, and
DEFINITE
2. Tendon xanthoma in the patient or
first/second degree relative, or
alternatively:
3. Presence of LDL-receptor, ApoB, or
PCSK9 mutation
1. In adults: TC >7.5mmol/L (or, when
available, LDL >4.9mmol/L) and in
pediatric patients: TC >6.7mmol/L, or
LDL >4.0mmol/L, and
POSSIBLE
2. Family history of MI <50 y.o. in second
degree relative or <60 y.o. in first degree
relative or, alternatively,
3. Family history of TC >7.5mmol/L in a
first- or second-degree relative
FH, Familial hypercholesterolemia; TC, Total cholesterol; LDL, Low density lipoprotein;
MI, Myocardial infarction; ApoB, Apolipoprotein B; PCSK9, Proprotein convertase
subtilisin/kexin type 9; y.o., Years old.
subsequently investigate the significance of the rare or unknown
variants if present (Reiman et al., 2016). Of note, in cases
where no pathogenic variant is detected in the four genes
(LDLR, ApoB, PCSK9, and LDLRAP1), NGS is expected to
successfully differentiate the polygenic type of the disease
through whole/targeted genome, or whole exome sequencing
(Hartgers et al., 2015; Bell and Watts, 2016), which is performed
through the Genomics England 100K Genomes Project since
2013 in the UK (Turnbull et al., 2018). Braenne et al. confirmed
the significance of exome sequencing in detecting small
nucleotide variants and large rearrangements leading to FH
phenotypes in 2016, and highlighted the need of co-segregation
analysis in order to identify the role of these variants. As the FH
diagnosis is often missed, even in CAD patients, it is suggested
that systematic and organized variant analysis is applied in the
future (Brænne et al., 2016).
As aforementioned, according to the UK NICE guidelines,
genetic testing could guide clinicians toward accurate diagnosis
and prognosis, as well as timely management in FH cases.
However, although genetic testing is considered to be cost-
effective, it should not be overlooked that the circulating LDL
levels determine the associated CVD risk and not the mutation
itself (Hovingh et al., 2013). Of note, HDL levels may be also
found normal or low, potentially due to increased ApoA-I
turnover and catabolism of dysfunctional HDL by the ApoE-
receptor (Ooi et al., 2013). Moreover, due to the high number
of pathogenic variants and the low detection rates of the existing
methods, genetic testing for FH remains inadequate in countries
with greater genetic heterogeneity (Health Quality Ontario, 2007;
Haralambos et al., 2016; Sharifi et al., 2016; Fairoozy et al., 2017).
It is worth noting that reaching the diagnosis may be
particularly complicated in FH cases due to the polygenic
inherited form. It is now known that many hypercholesterolemia
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TABLE 4 | Dutch Lipid Network criteria for diagnosis of familial
hypercholesterolemia.
DUTCH LIPID NETWORK SCORE
FAMILY HISTORY
Premature CVD (men <55 y.o., women
<60 y.o.) in first degree relative, or
1
LDL >95th percentile in first degree
relative and/or
1
Tendon xanthoma and/or arcus cornealis
in first degree relative, or
2
LDL >95th percentile in children <18 y.o. 2
PERSONAL HISTORY
Premature CAD in patient (men <55 y.o.,
women <60 y.o.), or
2
Premature cerebral or peripheral vascular
disease (men <55 y.o., women <60 y.o.)
1
CLINICAL EXAMINATION
Tendon xanthomas, or 6
Arcus cornealis <45 y.o. 4
LDL
≥8.5mmol/l (≥330mg/dl) 8
6.5–8.4mmol/l (250–329mg/dl) 5
5–6.4mmol/l (190–249mg/dl) 3
4–4.9mmol/l (155–189mg/dl) 1
Presence of functional LDLR mutation (in
the LDLR, ApoB or PCSK9 gene)
8
DIAGNOSIS ACCORDING TO OVERALL SCORE
Definite >8
Probable 6–8
Possible 3–5
Unlikely <3
FH, Familial hypercholesterolemia; CVD, Cardiovascular disease; CAD, Coronary artery
disease; LDL, Low density lipoprotein; LDLR, Low density lipoprotein receptor; ApoB,
Apolipoprotein B; PCSK9, Proprotein convertase subtilisin/kexin type 9; y.o., Years old.
TABLE 5 | National Lipid Association (NLA) diagnostic criteria for familial
hypercholesterolemia.
NLA diagnostic criteria for FH
Children, adolescents,
young adults <20 y.o.
Adults ≥20 y.o.
LDL ≥4.1mmol/l (160mg/dl) LDL ≥4.9mmol/l (190mg/dl)
Non-HDL ≥4.9mmol/l (190mg/dl) Non-HDL ≥5.7mmol/l (220mg/dl)
FH, Familial hypercholesterolemia; NLA, National lipid association; LDL, Low density
lipoprotein; HDL, High density lipoprotein.
cases with none of the above pathogenic variants are related
to small-effect LDL-raising alleles (Talmud et al., 2013). The
development of a 12-single nucleotide polymorphism (12-
SNP) score has been found successful in differentiating healthy
individuals from FH patients without one of the three common
pathogenic variants (LDLR, ApoB, and PCSK9; Futema et al.,
2015). The polygenic type is also characterized by lower LDL
levels due to its more benign nature, which can be deceiving and
lead to false negative results (Hartgers et al., 2015).
TABLE 6 | Japanese diagnostic criteria for familial hypercholesterolemia.
Japanese diagnostic criteria for FH
1. Pre-treatment LDL ≥180mg/dl (≥4.6mmol/l)
2. Tendon xanthoma, or nodular skin xanthoma
3. Family history (within the second degree relatives): FH or premature CAD
FH, Familial hypercholesterolemia; LDL, Low density lipoprotein; CAD, Coronary artery
disease.
When genetic testing is not available or when a common
pathogenic variant is not found, the diagnosis should be based on
the LDL levels, the presence of atherosclerotic disease, response
to treatment, and family history (Ito andWatts, 2015;Watts et al.,
2015).
Finally, fasting lipid profile for FH testing should preferably
be avoided during acute illness (Watts et al., 2015) or chronic
concomitant illnesses (e.g., hypothyroidism, diabetes, liver, and
renal impairment) and certain medications should be excluded as
potential secondary causes (Hovingh et al., 2013; Hartgers et al.,
2015). A concise diagnostic algorithm is summarized in Figure 1.
CVD RISK ASSESSMENT IN FH
Once FH is diagnosed, a comprehensive CVD risk assessment
should be performed, since the prevalence of CAD among
FH patients can reach 33% (Benn et al., 2012). It is now
clearly demonstrated that carriers of FH pathogenic variants
present increased CVD risk when compared to non-carriers,
regardless of the LDL level, due to their persistent lifelong
hypercholesterolemia (Khera et al., 2016). It should be stressed
that, although the existing CVD risk assessment tools are helpful
in the general population, these are usually not able to accurately
predict the long-term CVD risk in FH patients. As such, the
arterial damage from the chronic exposure to high cholesterol
levels is generally under-estimated (Bouhairie and Goldberg,
2015). Interestingly though, a recent cross-sectional cohort
study demonstrated that the inclusion of age, HDL, gender,
hypertension, and smoking in the context of a cumulative clinical
score, named as the Montreal-FH-SCORE, can predict the CVD
risk in FH patients, regardless of their LDL levels (Paquette
et al., 2017a). It is also noteworthy that, Apo A-I and ApoB
apolipoproteins are considered as better CVD risk predictors
than LDL, even in patients who are on lipid-lowering treatment
(Walldius and Jungner, 2004).
Of note, triglycerides (TG) are not included in the diagnostic
criteria for FH, as their abnormal metabolism is not directly
linked to the disease. However, they are recognized as an
independent CVD risk factor and they are part of the general
management goals for CVD prevention (Catapano et al., 2016;
Jellinger et al., 2017). Thus, it is recommended that FH patients
would benefit from intensive advice against all risk factors,
including TG (Catapano et al., 2016).
Moreover, screening should evaluate the overall CVD risk
based on the smoking status, body mass index (BMI) and lipid,
glucose, and blood pressure profile of the patient, whilst taking
into account the presence of any atherosclerotic disease (Watts
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FIGURE 1 | Diagnostic approach/steps for suspected FH (based on Catapano et al., 2016; Jellinger et al., 2017). ASCVD, Atherosclerotic cardiovascular disease;
LDL, Low density lipoprotein; MEDPED, Make early diagnosis to prevent early death; WHO, World health organization; NLA, National lipid association; LDL, Low
density lipoprotein; TC, Total cholesterol.
et al., 2015). In HeFH, these variables predict the age of onset
and extent of CVD (Neil et al., 2008). Moreover, it has been
shown that the total cholesterol (TC) burden, calculated as TC
multiplied by age at diagnosis, plus annually assessed TC is linked
directly to coronary calcification (Gallo et al., 2017).
Arterial imaging (echocardiogram, cardiac computed
tomography, and angiography) can be used in order to evaluate
more accurately the degree of subclinical CVD (Walus-Miarka
et al., 2016). Such assessments should be offered at least to
high risk patients, since 25–90% of asymptomatic FH patients
have atherosclerotic plaques on carotid ultrasound (Khan
et al., 2011; van den Oord et al., 2013). Furthermore, a study
in 40 FH patients has also showed that their Carotid Intima-
Medial Thickness (CIMT) is significantly higher (0.7–1.83mm)
compared to controls (0.48–0.73mm) (Khan et al., 2011).
However, the significance of monitoring CIMT is not established
yet, since CIMT regression does not appear to directly correlate
with CVD outcomes, and coronary artery calcium might be
of greater prognostic value (Costanzo et al., 2010; Phan et al.,
2014).
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It is also worth noting that in pediatric FH cases the presence
of diabetes or Kawasaki disease with large aneurysms or chronic
kidney disease confers significantly higher risk and, thus, these
patients need even more intensified treatment (Watts et al.,
2015).
Recent guidelines recommend including lipoprotein (a)
[Lp(a)] in the CVD risk assessment of all FH patients (Watts
et al., 2015; Catapano et al., 2016), since Lp(a) levels 3.5-fold
higher than normal induce atherogenesis and increase the CVD
risk, especially in those with high LDL levels (Bucci et al.,
2016). Lp(a) is more abundant in HoFH, but it is also high
in HeFH (Sjouke et al., 2017). Existing data indicate that the
LDLR impairment is not responsible for the atherogenic profile
of Lp(a), but the underlying mechanisms are still not completely
understood (Cuchel et al., 2014b). Interestingly, Lp(a) has both
independent and synergistic effects to LDL on the cumulative
CVD risk [National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III), 2002;
Jacobson, 2013]. Being an independent CVD risk factor, this
parameter should be taken into account when setting the LDL
targets for each FH patient [National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III), 2002]. Notably, as will be described in the following
sections, niacin has been shown to effectively reduce Lp(a)
(Hovingh et al., 2013), but its use is limited due to its side effects
(Bucci et al., 2016), whilst other Lp(a)-lowering medications
include PCSK9 inhibitors, ApoB antisense oligonucleotides,
selective second generation apo(a) antisense oligonucleotides,
CETP inhibitors, thyroid hormone receptor agonists, estrogens,
and IL-6R mAbs (Ellis et al., 2017). Currently, the treatment of
choice for very high Lp(a) levels is LDL apheresis (Bucci et al.,
2016).
ORGANIZING CASCADE SCREENING IN
FH
After confirming the FH diagnosis of the screened patient
(“index” case), cascade screening of the patient’s family should
be arranged by a trained health care professional in order to
identify any relatives with the disease (Watts et al., 2015; Bell
and Watts, 2016). Screening involves assessing personal history
for the presence of hypercholesterolemia, phenotypic traits, and
premature CVD, along with a fasting lipid profile (Watts et al.,
2015). Strong collaboration between lipid specialist clinics and
general practitioners is essential for this system towork effectively
(Watts et al., 2015; Bell and Watts, 2016). Genetic testing is not
currently considered mandatory (Ito and Watts, 2015); however,
the current UK NICE guidelines suggest that it is cost-effective
(Kerr et al., 2017). When the mutation is known, it could be
used to continue the cascade screening (Catapano et al., 2016).
Of note, when a relative of the index case is diagnosed with
hypercholesterolemia/positive mutation, their own first-degree
relatives should be subsequently screened (Hovingh et al., 2013;
Catapano et al., 2016). Approximately half of the screened
relatives are expected to have FH due to the autosomal dominant
way of inheritance in most cases (European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011; Bell
and Watts, 2016).
In pediatric FH cases, according to the International FH
Foundation, it is generally recommended that screening should
start before the age of 10, usually between the age of 5 and 10
(Watts et al., 2015). The American College of Endocrinology
suggests consecutive screening of children at the ages of 3, 9, 11,
and 18 (Jellinger et al., 2017), and for adolescents >16 y.o. every
5 years or even more frequently if high CVD risk is suspected
(Jellinger et al., 2017). Diagnosis of HeFH is considered most
likely even in the absence of positive family history in children
>2 y.o. with LDL ≥5mmol/l (193mg/dl), while HoFH is usually
the case in children <10 y.o. with LDL >13mmol/l (Watts
et al., 2015). In cases of hypercholesterolemia or premature CVD
family history the diagnosis is set at LDL >4mmol/l (155mg/dl)
and at LDL ≥3.5mmol/l (135mg/dl) when a parent has been
diagnosed genetically (Catapano et al., 2016).
MANAGEMENT OF FH
FH patients should be advised that life-long management with
regular follow up will be required, since at the moment there
are no curative treatment options. In clinical practice, treatment
must be initiated as soon as possible, aiming to lower lipidemia,
particularly LDL (Turgeon et al., 2016; Migliara et al., 2017), at
levels which reduce the overall CVD risk to that of the general
population (Goldberg et al., 2011). As such, an individualized
management plan is required, taking into consideration that
typically the overall treatment approach for HoFH should be
more aggressive compared to HeFH (European Association
for Cardiovascular Prevention and Rehabilitation et al., 2011;
Bouhairie and Goldberg, 2015; Watts et al., 2015).
Setting the Targets for FH Treatment
Current strategies in the management of FH focus on specific
LDL targets, since compiling clinical evidence shows improved
outcomes through this approach (European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011).
Meta-analysis data from 26 randomized controlled trials
(RCTs) showed that reduction of LDL by 1mmol/l (40mg/dl)
directly correlates with a 22% CVD risk reduction (Cholesterol
Treatment Trialists et al., 2010). Accordingly, although different
treatment guidelines exist globally, a common treatment goal
in clinical practice is to achieve a 50% reduction of the initial
LDL levels (European Association for Cardiovascular Prevention
and Rehabilitation et al., 2011; Goldberg et al., 2011; Hovingh
et al., 2013; Bouhairie and Goldberg, 2015; Hartgers et al.,
2015). Of note, LDL targets should be the same for both
HeFH and HoFH patients (Najam and Ray, 2015), although
clinicians should keep in mind that FH patients at higher
overall CVD risk would benefit from more aggressive treatment
(Table 7). According to the 2016 European guidelines for FH
management, the recommended LDL target is <2.6mmol/l
(100mg/dl) or<1.8mmol/l (70mg/dl) in cases with concomitant
CVD (Catapano et al., 2016) (Table 8).
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TABLE 7 | Candidates for familial hypercholesterolemia treatment intensification.
Candidates for FH treatment intensification
(1) Patients with established arterial disease
(2) Patients with diabetes
(3) Patients with family history of premature CVD (<45 y.o. males and/or
<55 y.o. females),
(4) Smokers
(5) Patients with ≥2 risk factors for CAD
(6) Patients with Lp(a) >50mg/dl
(7) Patients with LDL >4.1mmol/l (>160mg/dl) and non-HDL >4.9mmol/l
(>190mg/dl)
(8) Patients not able to achieve the target of 50% LDL reduction
FH, Familial hypercholesterolemia; CVD, Cardiovascular disease; CAD, Coronary artery
disease; LDL, Low density lipoprotein; HDL, High density lipoprotein; Lp(a), lipoprotein
(a). Adapted from Bouhairie and Goldberg (2015) and Goldberg et al. (2011).
TABLE 8 | Therapeutic targets for familial hypercholesterolemia (2016 ESC/EAS
Guidelines for the Management of Dyslipidemias).
Therapeutic targets for FH
Patient population LDL target
Children <3.5mmol/l (<135mg/dl)
Adults without established CVD <2.6mmol/l (<100mg/dl)
Adults with established CVD <1.8mmol/l (<70mg/dl)
FH, Familial hypercholesterolemia; CVD, Cardiovascular disease; EAS, European
atherosclerosis society; ESC, European Society of Cardiology; LDL, Low density
lipoprotein; Adapted from Catapano et al. (2016).
Despite such guidelines and the well-established benefits of the
proposed target LDL levels, existing evidence indicates that often
FH patients remain under-treated. Indeed, a cross-sectional study
from the Netherlands on the management of HeFH in outpatient
clinics revealed that most of these patients failed to achieve the
desirable 2.5mmol/l threshold for LDL, since treating physicians
were accepting higher LDL levels with less intensified treatment
(Pijlman et al., 2010).
However, it is also not uncommon for FH patients with
very high pre-treatment LDL levels to fail reaching the desired
treatment targets despite intensified therapy. In such cases, new
realistic targets should be set with regular follow up, and, as a
general rule of practice, clinicians should aim for the maximum
LDL reduction withminimum side effects (European Association
for Cardiovascular Prevention and Rehabilitation et al., 2011;
Hovingh et al., 2013).
Finally, HDL has been identified as an additional parameter
which should be taken into account when planning the treatment
approach for FH patients. Currently, specific HDL targets are
not included in the existing clinical practice recommendations.
However, due to its beneficial role in reverse cholesterol
transport and its antioxidant/cardio-protective effects, higher
HDL levels are desirable (HDL ≥60mg/dl), and this has been
shown to enhance the benefits of lowering LDL [National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III), 2002].
Lifestyle Changes and a Holistic Approach
in the Management of FH
A holistic approach with a spectrum of lifestyle changes should
be adopted in the long-term management plan for FH patients,
aiming to optimize LDL levels (Goldberg et al., 2011) and reduce
the overall CVD risk (Arsenault et al., 2017).
Weight Control and FH
Taking into account the detrimental effects of increased
abdominal adiposity on the production of small dense LDL,HDL,
and on other parameters (e.g., pro-inflammatory circulating
adipokines) which collectively increase the CVD risk (Tchernof
and Despres, 2013), FH patients should be advised to maintain
a BMI within the normal range (European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011;
Goldberg et al., 2011; Watts et al., 2015). For obese FH patients,
an individualized strategy should be tailored to achieve and
maintain the desired weight loss through a multidisciplinary
approach (e.g., specialized input from dieticians and advice for
appropriate exercise; Goldberg et al., 2011; Najam and Ray, 2015).
Dietary Interventions in FH
Referral of FH patients for specialized dietary/nutritionist advice
is helpful in their long-term management (Najam and Ray,
2015). A diet low in saturated fats (total daily fat intake in the
range of 25–35%, with saturated fats <7% of overall intake),
low in cholesterol (<200 mg/day) and high in fiber (10–20
g/day) is generally advised for FH patients (Goldberg et al.,
2011; Hovingh et al., 2013; Cuchel et al., 2014b). Of note, such
dietary approaches/counseling in children with FH have also
been associated with improved lipid patterns (Torvik et al.,
2016). Of note, dietary fibers are known to lower LDL and TC
(Brown et al., 1999; Hartley et al., 2016), as well as diastolic
pressure (Hartley et al., 2016), potentially acting through altering
cholesterol absorption and specific hormonal signaling (Van
Horn, 1997); however, conclusive data on their long-term CVD
impact/outcomes are still insufficient (Malhotra et al., 2014;
Hartley et al., 2016).
Overall, following a diet low in saturated fat has been shown
to decrease LDL levels by 8–10%, while limiting cholesterol
consumption to <200mg daily appears to lead to a 3–5% LDL
reduction (Hovingh et al., 2013). However, diet alone is not
sufficient to significantly alter the progression of the disease in
most FH cases (Cuchel et al., 2014b).
Regarding specific dietary patterns, existing data suggest that
adhering to the Mediterranean diet may have multiple benefits.
Indeed, the Mediterranean diet (low in saturated fat and high
in monounsaturated fat and complex carbohydrates) has been
associated with a 30% reduction in major CVD events compared
to a low-fat diet alone (Barry et al., 2016).
Previous recommendations have also suggested daily
consumption of plant sterols for cholesterol reduction (Malhotra
et al., 2014). Plant sterols remove cholesterol from bile salt
micelles and affect cholesterol absorption, hence they can play
a role in cholesterol reduction (Hovingh et al., 2013). However,
larger randomized RCTs are needed in order to assess their
exact role in FH. A recent systematic review by Malhotra et al.
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that included 15 RCTs in FH patients compared the effect
of cholesterol-lowering diets vs. other dietary interventions
(e.g., plant sterols) on ischemic heart disease, as well as on
the number of deaths and age at death (Malhotra et al., 2014).
Overall, this systematic review reported no clear effect of these
dietary interventions on the studied primary outcomes, with
insufficient evidence to routinely recommend any of these in the
management of FH (Malhotra et al., 2014).
Exercise and FH
Increased physical activity is generally advised as part of
the overall management of dyslipidemias as it is associated
with favorable impact on metabolic risk factors [National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III), 2002; Jellinger et al., 2017].
Indeed, it seems to have a protective effect against atherosclerosis
and oxidative stress, specifically preventing early endothelial
dysfunction in LDLR-deficient mice (Guizoni et al., 2016).
However, caution is necessary in FH patients with established
arterial stenosis (ostial or aortic), due to the risk of impairing the
underlying hemodynamic status (Cuchel et al., 2014b). In such
cases, low-intensity exercise could be potentially recommended
when considered safe, as even this can impact on the overall
survival (Barry et al., 2016). For individuals who are safe to
exercise, it is recommended that they adhere to 60min of
daily aerobic exercise plus muscle-strengthening twice a week
(Jellinger et al., 2017).
Alcohol and FH
In the context of the long-term management and CVD risk
reduction in FH, alcohol consumption should be limited
(Goldberg et al., 2011). Light/moderate alcohol intake (up to
10 g daily) has been associated with lower CVD risk, mostly due
to elevation of HDL and improved insulin sensitivity; however,
high alcohol intake leads to increased CVD risk (de Jesus et al.,
2016). According to the UK NICE guidelines, as for the general
population, the recommended alcohol intake should not exceed
3–4 units/day for adult men and 2–3 units for women, while
it is also important to avoid binge drinking (www.nice.org.uk/
guidance/CG71).
Smoking Cessation
Smoking represents another key factor in the plan for CVD
risk reduction in FH patients (Goldberg et al., 2011), as it
is known to affect several proteins which participate in the
atherosclerosis process (Huang et al., 2016). This should be
addressed rather aggressively in all FH patients who report
smoking (Goldberg et al., 2011; Najam and Ray, 2015; Turgeon
et al., 2016), and referral to specialized centers for smoking
cessation should be offered, if necessary (Nordestgaard et al.,
2013). Moreover, young patients with FH and their families
should be thoroughly informed and strongly advised to avoid
starting smoking (Nordestgaard et al., 2013).
Optimization of Blood Pressure
Optimizing the blood pressure control in FH patients should
also not be overlooked as part of the approach to prevent
premature atherosclerotic disease (Turgeon et al., 2016), since
elevated blood pressure is a well-established CVD risk factor
(Goswami and Manohar, 2016; Rust and Ekmekcioglu, 2016).
Blood pressure targets for FH patients should be set at <140/90
mmHg or at<130/80mmHg for patients with diabetes (Goldberg
et al., 2011).
Statin Treatment in FH
Despite careful planning and strict adherence to a healthy
lifestyle, the vast majority of FH patients will eventually require
lipid-lowering drug therapy. Thus, drug therapy should be
promptly initiated when after a trial period of lifestyle changes
the levels of LDL and TC remain ≥4.9mmol/l (≥190mg/dl) and
≥5.7mmol/l (≥220mg/dl), respectively (Goldberg et al., 2011).
Currently, statins represent the first step in the pharmacologic
treatment of FH. Statin treatment should be ideally initiated at
the age of 8–10 for children with HeFH, and as soon as the
diagnosis is made for HoFH patients (Kolansky et al., 2008;
Bouhairie and Goldberg, 2015).
Statins are selective HMG-CoA reductase inhibitors, resulting
in LDL lowering (Hartgers et al., 2015; Watts et al., 2015). This
is followed by the activation of the sterol regulatory element
binding protein-2 (SREBP2), a transcription factor which
subsequently up-regulates the expression of LDLR in hepatocytes
(Huff et al., 2014). This up-regulation leads to enhanced clearance
of LDL and other Apo-B containing lipoproteins from the
circulation. Statins have been extensively studied in large clinical
trials and have well-established benefits on CVD morbidity and
mortality (European Association for Cardiovascular Prevention
and Rehabilitation et al., 2011). Moreover, statins are also useful
in secondary prevention, improving CVD outcomes in patients
with established CAD (Hovingh et al., 2013).
Early intervention in HeFH with statins has shown to
markedly decrease LDL levels (up to 60%), but this reduction can
reach only up to 20% in HoFH patients (Hovingh et al., 2013).
Of note, statin-treated FH patients have been shown to exhibit
similar arterial imaging as subjects in the general population (Bos
et al., 2017).
Furthermore, statins seem to increase HDL levels through
blocking by 30% the activity of the cholesteryl ester transfer
protein (CETP; a protein mediating the transfer of lipids between
HDL and ApoB-containing particles; Postmus et al., 2016). The
overall effect of statins on HDL levels appears to depend on
genetic variations of the CETP locus (Postmus et al., 2016), as well
as on the baseline HDL levels and the level of the HDL-bound
anti-oxidative enzyme paraoxonase-1 (PON1) (Himbergen et al.,
2005).
Among the available statins, pravastatin is approved for
use in patients over 8 years old by the US Food and
Drug Administration (FDA), whereas lovastatin, atorvastatin,
simvastatin, and rosuvastatin can be used after the age of 10
(Bouhairie and Goldberg, 2015). The latter three statins together
with pitavastatin are classified as moderate to high potency
statins, and represent the first line choices in FH. Prescribing
maximum doses of atorvastatin and rosuvastatin seems to
be the general rule (European Association for Cardiovascular
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Prevention and Rehabilitation et al., 2011; Bouhairie and
Goldberg, 2015).
It is noteworthy that, the pharmacokinetic properties of
different statins vary significantly (Benes et al., 2016). Most of
the statins are mainly metabolized in the liver by cytochrome
P450 enzymes, with the exception of pravastatin, rosuvastatin,
fluvastatin, and pitavastatin [National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III), 2002; Benes et al., 2016], which should be preferred
with concomitant use of CYP3A4 inhibitors (Benes et al., 2016).
The lipid-lowering effect depends also on other factors, including
the absorption, metabolism, dietary habits, compliance, genetic
background, ApoE phenotype, gender and hormonal status
[National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III), 2002].
Accordingly, the effects of statin treatment on CIMT have been
shown to differ based on the potency and dose of the prescribed
statin, with aggressive treatment resulting in CIMT regression
(Smilde et al., 2001).
In the context of an individualized management plan, it
is suggested that FH patients are involved in the decision
making process regarding statin treatment. As such, the overall
CVD risk should be assessed, LDL-lowering targets should be
agreed with the patient, and a statin that could potentially
provide the desirable effect should be then initiated (European
Association for Cardiovascular Prevention and Rehabilitation
et al., 2011). Subsequent fine-tuning will be required until
the LDL target is reached, with data suggesting that doubling
of the statin dose can lead to a further reduction in LDL
by 6% [National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III),
2002].
Despite the established benefits of statin treatment in FH,
current data indicate that statins are not offered to all FH patients
in routine clinical practice, with a study in an unselected Danish
population reporting that at least half of the FH patients were
not on lipid-lowering treatment (Benn et al., 2012). Therefore,
targeted efforts are still required in order to address various
barriers to prompt and appropriate FH treatment.
Side effects from statin treatment constitute one of the
key barriers/problems in the management of FH patients.
Clinical trials involving medium-term follow-up of statins
offered to children have concluded that these are both
effective and safe (Goldberg et al., 2011). However, side
effects such as myopathy (rarely rhabdomyolysis) and elevated
liver enzymes (rarely hepatotoxicity) have been reported,
without outweighing the overall significant benefit on CVD
(Bouhairie and Goldberg, 2015). Notably, data from RCTs
comparing statins against placebo on more than 129,000 patients
show significant correlation of statin-induced side effects with
advanced age, small body size, female gender, renal and liver
impairment, hypothyroidism, perioperative time-frame, multi-
organ pathology, and alcoholism (European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011).
Myopathy constitutes the most frequent (5–15%) side effect
of statins, with rhabdomyolysis being its most dangerous form
(Pasternak et al., 2002; Catapano et al., 2016). Muscle cell damage
and death (rhabdomyolysis) result in the release of creatine
phosphokinase (CK) and myoglobin among other intracellular
molecules, while the accumulation of myoglobin in the kidneys
can lead to renal failure and death (Pasternak et al., 2002;
Tomaszewski et al., 2011; Catapano et al., 2016). Death associated
with statin-induced rhabdomyolysis is considered extremely rare:
<1 death/million statin prescriptions (Pasternak et al., 2002) and
7.6% in patients with statin-related rhabdomyolysis (Holbrook
et al., 2011), while case reports link these fatal events with
concomitant medications, like cancer treatment (Nelson et al.,
2017) and non-steroid anti-inflammatory drugs (Noordally et al.,
2012). CK is commonly used as a marker to monitor muscle cell
damage in statin-treated FH patients (Catapano et al., 2016).
Statin-induced myopathy could be justified genetically in
certain cases, based on previous findings from the SEARCH
genome-wide association study which has identified a SNP in the
SLCO1B1 gene as a potential risk factor (Stewart, 2013). Other
SNPs associated with myopathy are the polymorphisms in the
ABCB1 and ABCG2 genes (Ferrari et al., 2014).
In cases with severe myalgia, investigations for underlying
vitamin-D deficiency or hypothyroidism are recommended,
since management of such concomitant disorders has been found
to increase the tolerability to statins (Saxon and Eckel, 2016).
Ubiquinone (coQ10) is another factor that might interact
with statins and play a role in the reported side effects
(Saxon and Eckel, 2016). This coenzyme mediates the aerobic
respiration in mitochondria through electron transport (Ernster
and Dallner, 1995), and statins have been found to impede its
production via inhibition of the mevalonate pathway (Saha and
Whayne, 2016; Saxon and Eckel, 2016). In turn, coQ10 deficiency
has been reported to correlate with statin-induced myopathy
(Choi et al., 2016; Latkovskis et al., 2016; Saha and Whayne,
2016), possibly through ubiquinone-mediated impairment of
cellular metabolism (Choi et al., 2016). However, a meta-
analysis of RCTs failed to show significant alleviation of statin-
associated myalgia by coQ10 supplementation (Banach et al.,
2015).
In clinical practice, detailed history and clinical examination
are always required when evaluating reported side effects from
statin treatment. The type of symptoms, timing, and dose of
statin, as well as concomitant treatments and disorders should be
recorded. For example, rare, rheumatologic diseases (e.g., giant
cell arteritis and polymyositis) may be simultaneously present,
hence further investigations (e.g., ESR and CRP) may be required
upon clinical suspicion (Saxon and Eckel, 2016). The precise
description of muscle symptoms can be helpful in order to
establish a probable, possible, or unlikely causal relationship with
statins, according to existing scoring systems (Saxon and Eckel,
2016).
In addition to monitoring CK elevations, liver function
tests should be also evaluated in statin-treated FH patients
(Saxon and Eckel, 2016), including transaminases (aspartate
aminotransferase, AST or SGOT, and alanine aminotransferase
ALT or SGPT) which are markers of hepatocellular damage
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(Bolondi et al., 2016). Liver function tests have been found
abnormally elevated (in a dose-dependent way) in 0.5–2% of
statin-treated patients (Catapano et al., 2016). Although statin-
induced elevations in transaminases, especially without parallel
bilirubin elevations, are not associated with hepatotoxicity
(Herrick et al., 2016), ALT and AST should be assessed, together
with CK, at baseline (before the initiation of statin treatment).
Then the levels of transaminases should only be reassessed after
8–12 weeks of treatment initiation or increase. Routine follow-
up monitoring is currently not recommended. However, if these
are elevated, but remain <3 times the upper reference limit
(URL), follow-up tests should be repeated in 4–6 weeks without
the need to stop the treatment, whereas levels >3 times the
URL require treatment cessation, re-evaluation in 4–6 weeks, and
careful re-challenge when normalized (Catapano et al., 2016).
Routine CK measurements in asymptomatic patients are also
not essential, unless the patient develops myalgia (Catapano
et al., 2016). In cases presenting with serious side effects from
statin treatment, a referral to a Lipid Specialist physician is
required for appropriate discontinuation and potentially a re-
challenge strategy (Saxon and Eckel, 2016). Of note, CK cut-offs
applied for statin discontinuation differ among specialists and
usually local protocols are followed, with Saxon et al. suggesting
discontinuation and subsequent repeated renal function tests for
CK >10 times the URL (Saxon and Eckel, 2016). The most
recent European guidelines for the management of dyslipidemias
now recommend the same CK cut-off (>10 × URL) for statin
discontinuation, whilst lower CK levels can be considered in
case of persistent muscle symptoms (Catapano et al., 2016).
Other statin-related side effects appear to include multiple
sclerosis, lung disease, hemorrhagic stroke and increased risk
of type 2 diabetes mellitus (T2DM) (European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011; Barry
et al., 2016; Collins et al., 2016). Available data on memory
loss in statin-treated elderly patients show neither harm nor
benefit, but better designed studies are still required to explore
this issue (Samaras et al., 2016). So far, it appears that there
is no causal relationship between the spontaneously reported
cognitive symptoms and statins (Rojas-Fernandez et al., 2016).
Moreover, a systematic review exploring the relation of statins
to tendinopathy showed very limited evidence to support the
initial hypothesis, whereas particularly simvastatin was strongly
correlated with a reduced tendinopathy risk (Teichtahl et al.,
2016).
Increased T2DM incidence has been previously reported in
clinical trials with statins, but there is some inconsistency in
reported findings. Indeed, a study in FH and familial combined
hyperlipidemia (FCH) patients failed to show a relationship
between high-intensity statin treatment and new onset diabetes
(Skoumas et al., 2014). However, a meta-analysis of large RCTs
with a minimum 1-year follow-up of statin therapy showed
a slight increase in diabetes incidence in hypercholesterolemic
patients, mostly treated with atorvastatin and rosuvastatin (Rahal
et al., 2016). Underlying diabetes at treatment initiation, intensity
of treatment, and lifestyle are considered associated with the
diabetes risk in statin-treated patients. To date, the proposed
underlying mechanisms for this link involve impaired pancreatic
Box 1 | Adjustment maneuvres for treating FH patients with the maximum
tolerated statin dose (Tziomalos et al., 2010; European Association for
Cardiovascular Prevention and Rehabilitation et al., 2011; Bouhairie and
Goldberg, 2015; Saxon and Eckel, 2016).
Adjustment maneuvers for FH patients treated with the maximum
tolerated statin dose
• Statin treatment should be stopped if severe symptoms are present.
Further discussion with the patient should aim at statin re-challenge when
the reported symptoms are alleviated (this approach also allows to evaluate
the causative relation to statin use)
• The same intensity statin group can be maintained; however, on a lower
dose (maximum tolerated dose)
• In case of only mild symptoms, the patient should be offered any statin that
hasn’t been previously tried (starting with the hydrophilic statins, such as
rosuvastatin and pravastatin)
• Patients on a high-potency statin (e.g., atorvastatin or rosuvastatin) may
be switched to an alternate day regimen, or even less often if necessary
• Statin treatment may be switched to a lower intensity statin group on a
nightly or an alternate day regimen with a plan for a slow titration
• Other lipid-lowering drugs should be added when treatment with only a
low statin dose can be maintained and in severe intolerance when statins
should be substituted completely
FH, Familial hypercholesterolemia; CVD, Cardiovascular disease; CAD,
Coronary artery disease; LDL, Low density lipoprotein; HDL, High density
lipoprotein; Lp(a), lipoprotein (a).
β-cell activity and insulin resistance due to enhanced cellular
uptake of cholesterol and pro-inflammatory effects of statins
(Ganda, 2016). Additionally, the association of rs17238484-G
(a genetic polymorphism of the HMG-CoA reductase gene)
with increased diabetes risk could potentially offer another
explanation for the diabetogenic effect of statins (Swerdlow et al.,
2015). Despite these findings, it has been shown that the overall
CVD benefit of statins outweighs the diabetes risk in statin-
treated patients (Maki et al., 2016).
As the objective of the individualized treatment plan is to keep
FH patients on the maximum tolerated statin dose, a series of
adjustment maneuvres have been proposed in the literature to
better guide the clinical practice. These are outlined in Box 1
and should be applied in close collaboration with the patient. Of
note, although these maneuvres seem to be useful in everyday
clinical practice, the exact impact on CVD outcomes in patients
receiving these modified treatment regimens have not been fully
assessed yet, and the available data from clinical trials are not
considered sufficient to support an evidence-based consensus
(Arca et al., 2012). However, prescribing the maximum tolerated
statin dose, with the addition of a non-statin lipid-lowering
treatment when indicated, appears to remain the most effective
treatment approach in FH patients (Miedema and Virani, 2016).
Indeed, as long as even a moderate statin dose is maintained the
overall CHD risk can still be significantly reduced (Versmissen
et al., 2008). Accordingly, it is crucial that FH patients are
informed of the substantial evidence from RCTs showing that the
treatment benefits outweigh the risk of side effects in order to
reinforce the appropriate use of statins and achieve better clinical
outcomes (Collins et al., 2016).
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Additional Lipid-Lowering Options in FH
Combination therapy is required in FH patients failing to
achieve the desired LDL goals with the maximum tolerated
statin treatment (Catapano et al., 2016). The choice of additional
lipid-lowering therapy should be based on the assessment
of co-existing factors, such as personal history, concomitant
medications, the complete lipidemic profile, and risk factors
which could precipitate side effects (e.g., myositis; Goldberg et al.,
2011). SNPs related to myopathy, like the SLCO1B1, ABCB1, and
ABCG2 gene polymorphisms (Stewart, 2013), could be taken into
account when considering combined treatment with statins.
Cholesterol Absorption Inhibitors in FH
Ezetimibe selectively blocks the absorption of dietary cholesterol
by the intestinal cells and increases cholesterol secretion into the
bile at the same time, through interfering with the Niemann-
Pick C1-like 1 protein (NPC1L1; Hovingh et al., 2013;McPherson
and Hegele, 2015). This leads to reduced intrahepatic cholesterol
concentrations and consequent LDLR up-regulation, hence the
circulating LDL levels are effectively decreased (Hartgers et al.,
2015; Catapano et al., 2016). Interestingly, loss-of-function
pathogenic variants of NPC1L1 have not only been associated
with reduced LDL levels, but also with a relative 53% decrease in
CVD risk, thus drawing more attention as a potential target for
CAD management (Myocardial Infarction Genetics Consortium
et al., 2014).
Data from clinical trials investigating the ezetimibe effect on
LDL show a reduction potential of 15–20%, which is similar
either as monotherapy or as an add-on to statin (Hovingh et al.,
2013; Hartgers et al., 2015; Catapano et al., 2016). Notably,
the combination of statin and ezetimibe appears to induce a
significant CVD reduction which is greater than that of statin
monotherapy (Cannon et al., 2015; Nussbaumer et al., 2016).
The absence of major side effects, interactions with statins,
or restrictions related to liver or renal impairment, renders
ezetimibe a relatively flexible treatment option (Catapano et al.,
2016). As such, ezetimibe is now considered a valuable weapon in
the lipid-lowering arsenal for FH patients, and is recommended
as the agent of choice to add on to the maximum tolerated statin
dose when LDL targets are not reached, or as monotherapy to
statin-intolerant patients (Hartgers et al., 2015; Catapano et al.,
2016).
Bile Acid-Binding Exchange Resins in FH
Cholesterol is partly utilized by hepatocytes to form bile
acids, which are secreted to the duodenum and reach
the terminal ileum where they are mostly reabsorbed into
the enterohepatic circulation. Bile sequestrants disrupt this
enterohepatic circulation by combining with bile constituents
and preventing their reabsorption. In turn, this leads to increased
bile acid excretion via the gastrointestinal (GI) tract and increased
utilization of hepatic intracellular cholesterol to form new bile
acids (Catapano et al., 2016). In addition, LDLR activity in
hepatocytes is also enhanced, resulting in greater LDL absorption
and decreased circulating LDL levels (Hovingh et al., 2013;
Catapano et al., 2016). Commonly used bile acid exchange
resins include colestipol, cholestyramine, and colesevelam, with
the latter being a newer drug which appears to have better
tolerance, fewer GI side effects and fewer interactions with other
medications (Robinson and Keating, 2007; Sonnett et al., 2010;
Catapano et al., 2016). Indeed, colesevelam is approved in the US
for the treatment of pediatric HeFH patients (10–17 y.o.), with
significant beneficial effects on lipid metabolism (Perry, 2010;
Lozano et al., 2016).
Overall, clinical trials have shown a potential reduction in
LDL plasma levels by 18–25% with resins, with a proportional
reduction in CVD (Catapano et al., 2016). Combined with
statins, these agents can add up to a 16% greater effect on
LDL reduction (Robinson and Keating, 2007). In addition to the
expected lipid-lowering effect, colesevelam has been shown to
also improve glycemic control (Staels, 2009), potentially acting
via suppression of the phosphoenolpyruvate carboxykinase, as
well as through enhanced secretion of glucagon-like peptide-
1, thus, down-regulating glycogenolysis and increasing insulin
secretion (Bays, 2014).
GI symptoms (e.g., flatulence and nausea) are the most
common side effects of bile acid sequestrants, which may be
alleviated by increased fluid intake. Furthermore, treatment
initiation in small increments and slow titration appears
effective in controlling these side effects, at least to some
extent. In addition, fat-soluble vitamin deficiency may be
induced by bile acid sequestrants, as well as increased levels of
triglycerides (TG) in predisposed patients. Finally, concomitant
ingestion of other drugs should be avoided in order to reduce
possible interference with their absorption/metabolism, with
the exception of colesevelam [National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III), 2002; Catapano et al., 2016; Turgeon et al., 2016].
In the management of FH, bile acid sequestrants may
be recommended either as monotherapy in younger patients,
pregnant women or women who want to become pregnant, and
patients requiring modest LDL reduction, or as combination
therapy with statins in patients with very high LDL levels
[National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III), 2002].
Nicotinic Acid in FH
Nicotinic acid (vitamin B3 or niacin) can be used in patients
with hypertriglyceridemia and mixed hyperlipidemias, as it
has been reported to increase HDL by 15–35%, whilst
decreasing TG by 20–50%, LDL by 5–25%, and Lp(a) by
30% [National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III),
2002; European Association for Cardiovascular Prevention
and Rehabilitation et al., 2011]. Nicotinic acid has also been
shown to reduce insulin sensitivity and impair glucose control
in T2DM patients [National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel
III), 2002]. However, its effects can be variable [National
Cholesterol Education Program (NCEP) Expert Panel on
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Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III), 2002].
Increased risk of myopathy when combined with statins is
a potential side effect of nicotinic acid (Turgeon et al., 2016).
Due to neutral CVD outcomes, lack of impact on mortality, and
certain side effects (e.g., skin toxicity) reported in two recent
trials, nicotinic acid is currently recommended for specific groups
of patients that are statin-intolerant, when other therapies have
failed to achieve the LDL targets (Najam and Ray, 2015).
Fibrates in FH
Fibrates (fenofibrate, bezafibrate, gemfibrozil, ciprofibrate) act as
peroxisome proliferator-activated receptor-α (PPAR-α) agonists,
resulting in decreased VLDL synthesis and increased TG
clearance. In addition, fibrates modestly increase HDL and
reduce TC and LDL levels [National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III), 2002; Catapano et al., 2016].
Even though fibrates can reduce CVD events in patients with
high TG and low HDL levels (Lee et al., 2011; Catapano et al.,
2016), these agents have not been shown to reduce all-cause
and CVD-related mortality and morbidity when added to statins
(Najam and Ray, 2015). Moreover, the addition of fibrates to
statins has been associated with higher incidence of myopathy,
rhabdomyolysis and liver dysfunction (Najam and Ray, 2015;
Turgeon et al., 2016), and particularly gemfibrozil should not
be co-prescribed with statins (Catapano et al., 2016). Thus,
fibrates could be considered as an additional option for LDL
lowering in HeFH patients, taking into account the increased
risk of side effects when added to statins (Najam and Ray, 2015;
Turgeon et al., 2016). Fibrates should be generally restricted
for treating diabetic patients with HDL <1mmol/l (<40mg/dl)
and LDL of 2.6–3.3mmol/l (100–129mg/dl), as add-on to
statins/monotherapy, for statin-intolerant patients when LDL
is ≥2.6mmol/l (≥100mg/dl) (Haffner and American Diabetes,
2004), and for patients with TG >4.5mmol/l (>170mg/dl) and
low HDL, although high dose statins alone may be also able to
achieve at least a moderate effect in these cases (Najam and Ray,
2015).
Fish Oils in FH
Fish oils have been previously found beneficial in the
management of FH, correlating with a less atherogenic lipid
profile in FH patients (Friday et al., 1991; Sala-Vila et al., 2013).
Moreover, fish oils may be cardio-protective, at least partly, by
reducing arterial stiffness and improving blood pressure (Pase
et al., 2011; Chan et al., 2016). However, the clinical benefits of
fish oil supplementation are not clear, and a recent meta-analysis
reported a weakness of fish oils to achieve significant positive
outcomes (Grey and Bolland, 2014).
Plasma Exchange in FH
An additional option in the management of FH patients is the
mechanical extraction of lipids. Initial trials of plasma exchange
in patients with HoFH and HeFH showed significantly reduced
cholesterol levels and improved life expectancy (Thompson et al.,
1975, 1985; Lupien et al., 1976; Berger et al., 1978).
The apheresis devices work through filtration of the pro-
atherogenic lipoproteins [LDL, VLDL, Lp(a)] (Gairin et al., 1990;
Moriarty and Hemphill, 2016). It must be noted that, plasma
exchange is a non-specific procedure which removes not only
LDL, but also albumin, immunoglobulins, coagulation factors,
fibrinolytic factors, and HDL. Thus, this particular treatment for
FH is considered problematic not only due to the high associated
cost, but also because of the increased rate of adverse events
and the poor outcomes related mostly to the non-specific HDL
removal from the circulation (Health Quality Ontario, 2007).
Moreover, difficult venous access in children could be a potential
limitation for this treatment (France, 2016).
Lipoprotein Apheresis in FH
Contrary to plasma exchange, lipoprotein apheresis is an
expensive, but highly effective procedure which removes
LDL (by 50–70%) and Lp(a) from the plasma through
an extracorporeal circulation filtering process (European
Association for Cardiovascular Prevention and Rehabilitation
et al., 2011; Hovingh et al., 2013). Cholesterol is removed by
binding to dextran sulfate or heparin molecules and subsequent
extracorporeal precipitation (Health Quality Ontario, 2007;
Moriarty and Hemphill, 2016). At a low pH, LDL, and Lp(a) are
co-precipitated with heparin and the complex is subsequently
removed by filtration of the closed loop (Health Quality Ontario,
2007).
In addition to removing cholesterol, heparin-induced
extracorporeal LDL precipitation (HELP) protects from
atherosclerotic damages by simultaneously filtering fibrinogen
and cellular adhesion molecules which also play a role in
atherogenesis (Health Quality Ontario, 2007).
The results of the procedure last for up to 2 weeks (Hovingh
et al., 2013), hence this is usually provided in weekly or
fortnightly intervals (European Association for Cardiovascular
Prevention and Rehabilitation et al., 2011), so that the LDL-
lowering effects may be maintained in the long-term (Health
Quality Ontario, 2007). The long-term benefits of the procedure
rely mostly in delaying atherosclerosis, whilst the biological
effects can be noted clinically via the regression/resolution of
xanthomas (Hovingh et al., 2013).
FH patients failing to reach the desirable LDL levels
despite appropriate pharmacotherapy or those with severe
atherosclerotic disease should be considered for lipoprotein
apheresis in specialized centers (Goldberg et al., 2011). However,
it should be taken into account that, lipoprotein apheresis
is a time-consuming procedure, which is further associated
with increased treatment costs, limited availability, difficulties
with venous access, especially for children and certain adverse
events (Health Quality Ontario, 2007; Hovingh et al., 2013).
The latter include blood loss, hypotension, anemia, chest pain,
headaches, flushing, abdominal discomfort, and arrhythmias,
with approximate incidence of 1–2% (Hovingh et al., 2013;
Moriarty and Hemphill, 2016). Moreover, a systematic analysis
has shown that FH patients treated with lipoprotein apheresis
may fail to achieve the target LDL goals of <2.5mmol/l
Frontiers in Pharmacology | www.frontiersin.org 14 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
TABLE 9 | Criteria for lipoprotein apheresis.
Criteria for LA
1997 US FDA
(≥6 months strictly low in cholesterol diet and maximum tolerated drug therapy)
(Health Quality Ontario, 2007)
2011 NLA
(≥6 months maximum tolerated drug therapy and functional FH) (Goldberg et al.,
2011)
• HoFH with LDL >13mmol/l (>500mg/dl)
• HeFH with LDL >7.8mmol/l (>300mg/dl)
• HeFH with LDL >5.2mmol/l (>200mg/dl) and CAD
• HoFH and LDL ≥7.8mmol/l (≥300mg/dl), or non-HDL ≥8.5mmol/l (≥330mg/dl)
• HeFH with LDL ≥7.8mmol/l (≥300mg/dl), or non-HDL ≥8.5mmol/l (≥330mg/dl),
and 0–1 risk factors
• HeFH with LDL ≥5.2mmol/l (≥200mg/dl), or non-HDL ≥6mmol/l (≥230mg/dl) and
≥2 risk factors, or Lp(a) ≥50mg/dl
• HeFH with LDL ≥4.1mmol/l (≥160mg/dl), or non-HDL ≥4.9mmol/l (≥190mg/dl)
and very high risk (established CAD, other CVD, or diabetes)
LA, Lipoprotein apheresis; FDA, Food and drug administration; NLA, National lipid association; FH, Familial hypercholesterolemia; HoFH, Homozygous familial hypercholesterolemia;
HeFH, Heterozygous familial hypercholesterolemia; LDL, Low density lipoprotein; HDL, High density lipoprotein; LP(a), lipoprotein (a); CAD, Coronary artery disease; CVD, Cardiovascular
disease.
(<100mg/dl), despite the overall reduction effect in LDL plasma
levels (Health Quality Ontario, 2007). Nevertheless, lipoprotein
apheresis should be considered when the expected benefits
exceed the associated risks. Indeed, based on a retrospective study
from one center in Germany, long-term lipoprotein apheresis
treatment in high risk patients with CVD was shown to be
well-tolerated, safe and effective, resulting in decreased LDL and
Lp(a) levels and markedly reduced CVD events by 80% during
a 6-year follow up period (Heigl et al., 2015). Additional data
from centers across Germany showed that lipoprotein apheresis
achieved lowering rates exceeding 60% for both LDL and Lp(a)
with a 90% decrease in major adverse coronary events (MACE;
Schettler et al., 2015).
In clinical practice, lipoprotein apheresis is generally
recommended for HoFH or HeFH refractory to diet and drugs
(Health Quality Ontario, 2007; Goldberg et al., 2011; Hovingh
et al., 2013; Catapano et al., 2016; Moriarty and Hemphill, 2016).
The 2011 NLA criteria are outlined and compared to previous
guidelines in Table 9. Indeed, due to the nature of HoFH, weekly
or biweekly lipoprotein apheresis represents one of the last
options in the management of such FH patients, along with
maximum doses of high potency statins (Health Quality Ontario,
2007; European Association for Cardiovascular Prevention and
Rehabilitation et al., 2011; Hovingh et al., 2013).
Recent Pharmacological Options in the
Treatment of FH
Treatment strategies in the management of FH have investigated
the potential role of certain additional options, including
microsomal transfer protein inhibitors, liver-selective thyroid
hormone mimetics, and oligonucleotides that supress ApoB
(mipomersen; European Association for Cardiovascular
Prevention and Rehabilitation et al., 2011; Hovingh et al., 2013).
Despite promising initial results, additional larger and longer
clinical trials are required to establish the exact role of these
options in the treatment of FH.
Lomitapide
Lomitapide is an oral drug which is approved for the treatment
of adults with HoFH (Cuchel et al., 2014a,b; Walsh and Hussain,
2016). Lomitapide acts by inhibiting the microsomal triglyceride
transfer protein in the liver, which is necessary for TG absorption
by the chylomicrons in the intestine and phospholipids by VLDL
in the hepatocytes (Cuchel et al., 2014b). Thus, lomitapide can
result in up to 50% reduction of LDL and 15% reduction of Lp(a)
levels at 26 weeks of treatment. Of note, its effect on LDL is
maintained, although to a lesser degree, from 26 to 78 weeks
of treatment, while Lp(a) levels return back to baseline at week
78 (Cuchel et al., 2013). Real-world data from a retrospective
study in Italy confirmed the LDL-lowering effect of lomitapide in
15 HoFH patients. Interestingly, follow-up data from this study
suggest that 80% of the patients undergoing lipoprotein apheresis
could avoid this procedure due to sufficient LDL reduction with
lomitapide (D’Erasmo et al., 2017).
Due to common metabolic pathways, co-administration of
lomitapide with CYP3A4 inhibitors should be avoided (Cuchel
et al., 2014b). Regarding potential side effects, a phase III trial
of lomitapide in HoFH patients has shown increased hepatic
fat content and elevation of transaminases, which resolved after
dose reduction (Cuchel et al., 2013). Hence, monitoring of liver
transaminases is necessary during lomitapide treatment (Najam
and Ray, 2015). In addition, GI adverse events have been also
reported (Cuchel et al., 2013; Stefanutti et al., 2016), whichmay be
addressed with slow dose titration, low-fat diet, and avoidance of
meal times (Cuchel et al., 2014b; Roeters van Lennep et al., 2015;
Stefanutti et al., 2016). Long-term observational studies, such
as the Lomitapide Observational Worldwide Evaluation Registry
(LOWER), are still required to better inform the clinical practice
on the exact safety and efficacy profile of lomitapide (Blom et al.,
2016).
Mipomersen
Mipomersen is an antisense oligonucleotide that binds ApoB
mRNA and subsequently down-regulates the expression of ApoB
by the ribosomes and the production of VLDL (Cuchel et al.,
2014b; Najam and Ray, 2015). Mipomersen is administered as a
200mg subcutaneous once-weekly injection (Hegele et al., 2015);
however, it has not been approved for use in Europe yet (Gaudet
and Brisson, 2015; Hartgers et al., 2015; Hegele et al., 2015).
Mipomersen is shown to decrease LDL levels by 21% in
patients with HoFH and by 28% in HeFH (Hartgers et al., 2015).
A phase III randomized, double-blind, placebo-controlled trial
Frontiers in Pharmacology | www.frontiersin.org 15 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
studying the addition of mipomersen on the maximum tolerated
standard lipid-lowering treatment in HoFH patients showed
significant reductions by up to 25, 27, and 31% in LDL, ApoB,
and Lp(a) levels, respectively (Raal et al., 2010). Positive lipid-
lowering results with mipomersen were also demonstrated in
pediatric patients, who were already on the standard of care
treatment (Raal et al., 2016a). Moreover, the reductions noted in
atherogenic lipoprotein levels with mipomersen correlated with
markedly lower incidence of MACE (Duell et al., 2016).
The most common adverse events of mipomersen include
transient injection-site reactions and flu-like symptoms, as well
as elevated ALT (<3 × URL in most patients; Akdim et al.,
2010; Raal et al., 2010). Mipomersen has also been associated
with increased intrahepatic TG content. Indeed, data from an
RCT trial showed that 1 in 10 treated patients exhibited reversible
(upon discontinuation) hepatic steatosis, while there was also a
trend for increased hepatic fat content in the rest of the patients
(Visser et al., 2010).
Overall, the use of mipomersen and lomitapide in clinical
practice is limited, and these agents are generally prescribed as an
add-on to statin treatment inHoFHpatients who cannot undergo
LDL apheresis (Hartgers et al., 2015).
Thyroid Mimetics
Thyroid hormones act on two main types of receptors, i.e.,
thyroid receptors α and β (TRα and TRβ; Villicev et al., 2007;
Lammel Lindemann and Webb, 2016). Endogenous thyroid
hormones exert lipid-lowering effects through TRβ; however, this
effect cannot be utilized for therapeutic purposes due to the
concomitant TRα-induced cardiac, muscle and bone thyrotoxic
side effects (Lin et al., 2012; Lammel Lindemann and Webb,
2016).
Development of selective TRβ agonists aims to circumvent
these problems and could potentially offer an additional
approach in FH treatment. Indeed, these thyromimetics can
induce hepatic bile acid production and up-regulate the
expression of the HDL receptor, i.e., the scavenger receptor
type B-Class I (SR-B1), leading to increased transport of
cholesterol into HDL particles, even though this effect was not
observed in LDLR−/− null mice (Lin et al., 2012). Thus, these
agents can interfere with cholesterol metabolism, without the
unwanted TRα-related side effects (Villicev et al., 2007). Data
from animal studies have shown that treatment of LDLR−/−
null mice with selective TRβ agonists, i.e., GC-1 (sobetirome)
and KB2115 (eprotirome), decreases serum cholesterol levels
by increasing cholesterol utilization for synthesis of bile acids
and inducing their subsequent fecal excretion in an LDLR-
independent manner (Lin et al., 2012).
Eprotirome administration exhibits a dose-dependent LDL-
lowering effect, with evidence from a phase III double-blind
RCT in HeFH patients (AKKA trial) indicating that daily oral
treatment with a 100µg dose can result in a 22% LDL reduction
compared to placebo after 6 weeks of treatment (Sjouke et al.,
2014). However, this study revealed that eprotirome treatment
has the potential to induce liver injury (Sjouke et al., 2014), and
was prematurely terminated due to other findings of eprotirome-
induced cartilage damage in dogs (Sjouke et al., 2014).
Sobetirome administration in various animal studies has
resulted in a remarkable LDL reduction, as well as in decreased
TG and Lp(a) levels in primates (Lammel Lindemann andWebb,
2016). Despite the absence of thyrotoxicity with the tested doses,
this agent appears to be associated with a mild suppression of
the hypothalamic-pituitary axis (Lammel Lindemann andWebb,
2016).
Overall, due to the reported side effects, there are doubts
about the potential role of selective thyroid receptor agonists as a
lipid-lowering therapeutic approach in FH patients. As such, the
future role of thyroid mimetics will depend on their safety profile
and some of these agents may potentially find a role in HoFH
treatment (Lammel Lindemann and Webb, 2016).
Proprotein Convertase Subtilisin/Kexin 9 (PCSK9)
Inhibitors
Proprotein convertase subtilisin/kexin 9 (PCSK9) is a serine
protease produced by hepatocytes (Najam and Ray, 2015).
PCSK9 blocks the LDLR recycling by mediating clathrin-
mediated endocytosis and subsequently inducing the lysosomatic
degradation of LDLR (Huff et al., 2014; Najam and Ray, 2015).
This leads to LDL accumulation in the circulation (Ferdinand
and Nasser, 2015), and eventually promotes atherogenesis, with
high PCSK9 levels correlating to the degree of coronary artery
calcification (Alonso et al., 2016).
PCSK9 gene pathogenic variants consist of either gain-
of-function (leading to high LDL levels), or loss-of-function
(associated with a 15–28% reduction in LDL levels and 47–
88% reduction in CVD risk) pathogenic variants (Najam and
Ray, 2015). The latter rendered PCSK9 inhibitors promising
therapeutic measures for FH. In addition to increasing LDL
plasma levels, PCSK9 gain-of-function pathogenic variants
have been found to increase circulating Lp(a) in FH patients
(Tada et al., 2016), potentially by interfering with Lp(a)
endocytosis, as shown in a human hepatocellular carcinoma
model (Romagnuolo et al., 2015). However, PCSK9 inhibition is
not sufficient to restore Lp(a) levels completely, suggesting that
additional factors are implicated, such as the up-regulation of
ApoB lipoproteins in FH patients (Tada et al., 2016).
To date, PCSK9 has been targeted using a variety of
techniques, such as antisense nucleotide therapy and monoclonal
antibodies aiming in uninterrupted LDLR expression and,
subsequently, substantial clearance of circulating LDL (by up to
70%; Hovingh et al., 2013; Seidah et al., 2014), with reduction
of ASCVD-related morbidity and mortality being the ultimate
benefit in atherosclerotic and FH patients (Eisen and Giugliano,
2016; Navarese et al., 2016; Sabatine et al., 2016, 2017).
Alirocumab and evolocumab (administrated subcutaneously
every 2 and 4 weeks, respectively) represent the two most
thoroughly tested PCSK9 inhibitors so far (Gouni-Berthold
et al., 2016; Ito and Santos, 2016). A recent meta-analysis of 15
RCTs showed good efficacy and safety data for FH and statin-
intolerant patients when administered at least for 8 weeks (Qian
et al., 2017). The reported side effects include mild injection-
site reactions (Hovingh et al., 2013), upper respiratory tract
infections, back pain and influenza (Blom et al., 2014) and very
rarely leucocytoclastic vasculitis (Hovingh et al., 2013).
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Overall, evolocumab appears to offer an attractive treatment
option for both HeFH and HoFH, even in statin-intolerant
patients and apart from significantly lowering LDL, it also
improves ApoA1, ApoB, Lp(a), non-HDL cholesterol, and
triglycerides, ultimately leading to atherosclerotic plaque
regression (Wiggins et al., 2018) and may be an alternative
solution for FH patients who cannot undergo lipoprotein
apheresis. Indeed, a recent study with a small number of
participants reported that lipoprotein apheresis showed no
superiority on LDL reduction over evolocumab (Lappegard et al.,
2016).
Similarly, the ODYSSEY ESCAPE trial demonstrated
significant efficacy of alirocumab in 62 HeFH patients
undergoing regular lipoprotein apheresis, with 63.4% of the
patients escaping lipoprotein apheresis treatment and 92.7%
having <50% of their scheduled sessions (Moriarty et al., 2016).
Overall, the ODYSSEY programme of phase III studies with
alirocumab has also reported positive outcomes, including
evidence in FH patients. This agent has also been well-tolerated,
with patients showing good adherence and it has resulted
in significant and persistent reductions in LDL, non-HDL
cholesterol, and Lp(a) levels (Farnier et al., 2016, 2017; Greig and
Deeks, 2016). Pooled data from the Odyssey trials have shown
that greater reductions in LDL [including LDL <1.3mmol/l
(50mg/dl)], are associated with fewer MACE (Ray et al., 2016).
It would be interesting to review the cardiovascular effects
of alirocumab when the detailed findings of the ODYSSEY
OUTCOMES trial are fully published. Data analysis from
14 trials on alirocumab have documented its safety (Jones
et al., 2016). Of note, a systematic review of 12 and 9 phase
III trials for alirocumab and evolocumab, respectively, in
hypercholesterolemic patients (including FH groups) showed
that alirocumab- and evolocumab-treated patients achieved the
desirable LDL targets with rates of 87 and 98%, respectively;
however, there was no head-to-head comparison between the
two drugs (Gouni-Berthold et al., 2016).
Both these PCSK9 inhibitors have been approved by
the FDA and the European Medicines Agency (EMA) for
HeFH, with evolocumab being also approved for HoFH as
additional treatment to diet and maximally tolerated statins for
patients at high CVD risk who have not reached their lipid
targets, or as replacement to statins when statin treatment is
contraindicated or not tolerated (Agabiti Rosei and Salvetti,
2016).
More data on two additional PCSK9 inhibitors, i.e.,
bococizumab and LY3015014, are being currently collected
(Dixon et al., 2016). Indeed, the SPIRE programme enrolling
>30,000 patients worldwide, including FH patients, has involved
six lipid-lowering and two CVD-outcome studies on the effects
of bococizumab (Ridker et al., 2016). Two randomized trials
(SPIRE 1 and SPIRE 2) have shown superiority of bococizumab
(humanized monoclonal antibody) in MACE only in high risk
patients when compared with placebo, however, the trials were
discontinued early by the sponsor due to high rates of anti-drug
antibodies (Ridker et al., 2017a). Similarly, the rest six parallel,
randomized trials with bococizumab have shown a significant
reduction in LDL at 12 weeks, however, the results were not
sustained for patients with high-titer antidrug antibodies at 52
weeks, whilst patients with no anti-drug antibodies presented
wide variation in LDL as well (Ridker et al., 2017b).
As for LY3015014, results so far seem promising with
significant reduction in LDL at week 16 and a good safety profile
(Kastelein et al., 2016).
Additional results of phase III studies with CVD-outcomes as
the primary end point are expected for PCSK9 inhibitors, such
as the FOURIER trial which has recently shown a significant
reduction on CVD events when adding evolocumab to statin
treatment in patients with clinically evident vascular disease
(Sabatine et al., 2017).
Due to their satisfying efficacy and safety profile, PCSK9
inhibitors seem to be currently the most promising additional
treatment in FH patients who are already on maximum
tolerated statin treatment (Reiner, 2015). The 2017 NLA Expert
Panel covers FH patients recommending PCSK9 inhibitor
treatment for patients with LDL ≥4.9mmol/l (≥190mg/dl)
and (i) 40–79 y.o., in the absence of poorly controlled
ASCVD risk factors and post-treatment LDL ≥2.6mmol/l
(100mg/dL) or non-HDL ≥3.4mmol/l (130mg/dL), while
on statin, with or without ezetimibe; (ii) 40–79 y.o., with
uncontrolled ASCVD risk factors, or genetic FH confirmation
and post-treatment LDL ≥1.8mmol/l (≥70mg/dl) or non-HDL
≥2.6mmol/l (≥100mg/dl), while on statin, with or without
ezetimibe; (iii) 18–39 y.o. with uncontrolled ASCVD or genetic
confirmation of FH and post treatment LDL ≥2.6mmol/l
(100mg/dL) or non-HDL ≥3.4mmol/l (130mg/dL), while on
statin, with or without ezetimibe; or for (iv) HoFH (unknown
genotype/LDLR defective), as additional LDL-lowering therapy,
when post-treatment LDL ≥1.8mmol/l (≥70mg/dl) or non-
HDL≥2.6mmol/l (≥100mg/dl), while on statin, with or without
ezetimibe, or before lomitapide, mipomersen and LDL apheresis
(Orringer et al., 2017). Table 10 summarizes the recent criteria
by ACC 2016 (updated in 2017) and ESC/EAS 2017 (updated in
2018), after taking into account the FOURIER outcomes for the
general use of PCSK9 inhibitors, including FH patients.
However, the high treatment costs (approximate $14,600
annually for alirocumab and $14,100 for evolocumab for HeFH
patients) of these agents may pose a barrier for their broader
use in routine clinical practice, and it is now known that there
should be significant cost reductions to approximately $4,536–
$5,459/year/patient to achieve their cost-effectiveness (Kazi et al.,
2016; Arrieta et al., 2017). Indeed, a recent Norwegian study has
shown that PSCK9 inhibitors are cost-effective only for high-
risk older patients during secondary prevention and especially
at prices as low as €63,200–68,400 per QALY (instead of the
current €81,406–84,646; Korman and Wisloff, 2018). Examples
of lifetime costs per patient are for: ezetimibe (€5,000–6,900),
PCSK9 inhibitors (€78,000–106,000) (Korman and Wisloff,
2018), and high dose atorvastatin (2005 data of incremental cost-
effectiveness ratio—$33,400 per QALY) (Plosker and Lyseng-
Williamson, 2007).
Cholesterylester Transfer Protein (CETP) Inhibitors
CETP induces the transport of cholesteryl esters and TG from
HDL molecules to atherogenic molecules, such as the ApoB-
containing lipoproteins (Hovingh et al., 2013). CETP inhibitors
include dalcetrapib, torcetrapib, anacetrapib, evacetrapib, and
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TABLE 10 | European and American Criteria for PCSK9 inhibitor use.
ACC (2016-updated in 2017) ESC/EAS (2017-updated in 2018)
INDICATIONS:
X Either a PCSK9 inhibitor or ezetimibe as a second line agent as an addition to
maximum tolerated statin for patients with clinical ASCVD with comorbidities
and baseline LDL ≥1.8mmol/l (70mg/dL).
X Should be preferred when >25% further reduction in LDL is required after
discussing all parameters with the patient
Specific criteria. Added to statin and ezetimibe:
(1) ASCVD without comorbidities and LDL ≥2.6mmol/L (100mg/dL) while on
maximum tolerated statin and ezetimibe and a reduction of LDL <50% from
baseline
(2) ASCVD with comorbidities and LDL ≥1.8mmol/l (70mg/dL), or non-HDL
≥2.6mmol/L (100mg/dL) in diabetic patients, while on maximum tolerated
statin and ezetimibe and a reduction of LDL <50% from baseline
(3) ASCVD with baseline LDL ≥4.9mmol/L (190mg/dL) and post-treatment LDL
≥1.8mmol/l (70mg/dL) while on maximum tolerated statin and a reduction of
LDL <50%, as an alternative to ezetimibe or bile acid sequestrant
(4) without ASCVD and LDL ≥4.9mmol/L (190mg/dL) and post-treatment LDL
≥2.6mmol/l (100mg/dL) while on maximum tolerated statin and a reduction
of LDL <50%, as an alternative to ezetimibe or bile acid sequestrant
(5) before LDL apheresis in HoFH patients, except LDLR negative patients
INDICATIONS:
X Adults with HeFH, non-familial hypercholesterolemia, or mixed dyslipidemia with
diet, maximum tolerated statin (or when statin-intolerant/contraindicated), or
other medications, not achieving LDL goals
X Adults and ≥12 y.o. with HoFH on other medications
X Symptomatic PAD
X Recurrent or recent MI
X Multivessel disease
Specific criteria: Added on statin and ezetimibe:
(1) Severe ASCVD and LDL >2.6mmol/L (100mg/dL)
(2) ASCVD and LDL >3.6mmol/L (140mg/dL)
(3) Diabetes with target organ disease or major risk factors (no ASCVD) and LDL
>3.6mmol/L (140mg/dL)
(4) HeFH without ASCVD and LDL >4.5–5mmol/L (175–200mg/dL) (according to
risk)
(5) HoFH (after maximum treatment, including LDL apheresis)—all patients except
from those with negative-negative LDLR mutations
(6) Statin intolerant patients on ezetimibe and any of the above criteria
Adapted from Writing et al. (2016), Lloyd-Jones et al. (2017), and Landmesser et al. (2017a,b); Landmesser et al. (2018). ACC, American College of Cardiology; ESC/EAS,
European Society of Cardiology/European Atherosclerosis Society; FH, familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; HeFH, heterozygous familial
hypercholesterolemia; LDL, low density lipoprotein; HDL, high density lipoprotein; PCSK9, proprotein convertase subtilisin/kexin type 9; ASCVD, atherosclerotic cardiovascular disease;
PAD, peripheral artery disease; MI, myocardial infarction.
TA-8995, which, apart from increasing HDL, with the exception
of the former, appear to decrease LDL plasma levels (Krahenbuhl
et al., 2016; Wang et al., 2018). However, despite this effect,
recent phase III outcome trials have shown limited benefits on
CVD outcomes when these agents are combined with the current
standard of care (McLain et al., 2016).
Anacetrapib, not only interferes with lipid exchange, but also
reduces LDL by increasing ApoB100-LDL binding to LDLR and
removing ApoB from the circulation (Hartgers et al., 2015). As
such, the phase III RCT (REALIZE) with anacetrapib as lipid-
modifying therapy in HeFH patients demonstrated significant
reduction in LDL by 36% after 1 year of treatment with good
tolerability (Kastelein et al., 2015). Moreover, the recent REVEAL
study has interestingly shown fewer MACE with anacetrapib vs.
control in patients with atherosclerotic vascular disease (Group
et al., 2017), however, as the greater results were observed much
later in years of treatment, this could pose a compliance issue and
make it difficult to be successful in real world (Doggrell, 2018).
Torcetrapib has been found to increase HDL by 72.1% and
lower LDL by 24.9% in a RCT comparing the combination
of torcetrapib and atorvastatin to atorvastatin alone, but this
trial was terminated due to increased morbidity and mortality
of unspecified pathogenesis (Barter et al., 2007). Moreover, a
dalcetrapib trial in patients with recent acute coronary syndrome
events showed poor efficacy when added to standard of care
treatment, failing to reduce CVD recurrence (Schwartz et al.,
2012).
Despite favorable effects on atherogenic lipoprotein-reduction
(Nicholls et al., 2016), evacetrapib was also abandoned due to
lack of improved CVD outcomes (Filippatos et al., 2016). Finally,
despite good results on lipid metabolism with TA-8995, large
outcome trials are also needed in order to establish its impact
on CVD (Hovingh et al., 2015a; Filippatos et al., 2016; van
Capelleveen et al., 2016).
ATP-Citrate Lyase (ACL) Inhibitor
The ACL inhibitor ETC-1002 (bempedoic acid) has been found
to lower cholesterol biosynthesis by depriving cells of the
necessary substrates. To date, studies either as monotherapy or
as combination therapy with statins have shown positive results,
without significant side effects (Bilen and Ballantyne, 2016;
Lammel Lindemann and Webb, 2016). The promising LDL-
lowering effects of ETC-1002 from phase II trials remain to be
confirmed by a phase III programme assessing its efficacy, safety
and long-term outcomes (Bilen and Ballantyne, 2016). Since this
agent has been also found to reduce C-reactive protein levels,
better CVD outcomes may be possible through its implication in
pro-inflammation processes (Penson et al., 2017).
Plaque Regression Treatment (rHDL) in FH
Intravenous infusion of reconstituted HDL or a HDL-mimetic
particle (CER-001) has shown encouraging results in reversing
coronary atherosclerotic damage (Hovingh et al., 2013; Kootte
et al., 2015), even in HoFH patients (Hovingh et al., 2015b).
CER-001, a pre-beta HDL-mimetic, acts potentially by promoting
reverse cholesterol transport and increasing the concentration
of ApoA-I. However, sufficient delivery of this agent to
atherosclerotic plaques through IV infusion remains a key
challenge for this approach (Hovingh et al., 2013; Zheng et al.,
2016).
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TABLE 11 | Summary of management options for familial hypercholesterolemia (FH) patients.
Treatment option Mechanism of action Effect on lipid metabolism Comments
Low in cholesterol—saturated fat
diet
Reduces cholesterol intake Up to 10% reduction in LDL Better CVD outcomes. Must be
recommended to all patients along with
other lifestyle changes (smoking
cessation, alcohol restriction, exercise,
blood pressure, and glucose control)
Plant sterols Affect cholesterol absorption Not statistically significant results Cannot be routinely recommended
Statins Inhibition of HMG-CoA reductase Up to 80% LDL reduction in HeFH and 20% in
HoFH
Important protective impact on CVD
outcomes. First line treatment in FH
Ezetimibe Blocks intestinal cholesterol
absorption through the
Niemann-Pick C1-like 1 protein
15–20% decrease in LDL Next add-on drug to statins for even
greater CVD protective effect, or as
monotherapy for statin-intolerant patients
Bile acid sequestrants ↑ Feacal excretion of bile acids
and LDLR up-regulation
18–25% LDL reduction as monotherapy and 16%
additional effect with statins
Useful in statin-intolerant patients and
pregnant women
Fibrates PPAR-α agonists (↓VLDL
synthesis and ↑TG clearance)
0.4–6% increase in HDL and 15–40% decrease in
LDL
Limited use due to side effects, neutral
CVD outcomes-restricted mostly to
patients with ↑TG and ↓HDL
Niacin Unclear—↓VLDL synthesis 25% increase in HDL, 20–40% decrease in TG,
15–18% reduction in LDL and 30% reduction in
Lp(a)
Limited use due to side effects, neutral
CVD outcomes
Fish Oils Less atherogenic lipid profile
(fewer/larger LDL particles,
more/larger HDL particles)
20% reduction in TG, 8% decrease in ApoB Inconsistent findings-recently deemed
cardio-protective through increased
arterial elasticity results
CETP inhibitors Inhibit CETP which mediates
transport of cholesteryl esters
and TG from HDL to
ApoB-containing lipoproteins
Up to 25% LDL reduction and 72% HDL increase Neutral CVD outcomes and increased
mortality in some cases
Thyromimetics Selective TRβ agonists: form bile
acids and up-regulate SR-B1
Approximately 22% reduction in LDL Restricted use due to side effects
PCSK9 inhibitors Block normal LDLR recycling LDL reduction: up to a 55% as monotherapy, and
75% combined with a statin
Promising results, but expensive. Good
CVD outcomes in recent studies
Lomitapide Inhibit MTTP which mediates TG
and phospholipid absorption
Up to a 50% decrease in LDL and 15% in Lp(a) Liver and GI side effects. Need for
additional safety trials
Mipomersen Down-regulating ApoB mRNA Up to 25% LDL and 31% Lp(a) reduction Limited use due to side effects
Lipoprotein apheresis Selective mechanical lipid
removal
Up to 50–70% LDL reduction Highly effective, but, due to reasons
relating to cost, availability,
time-consumption, and adverse events,
use is restricted in HoFH or refractory
HeFH cases
Liver transplantation Introduces new functional LDLRs Up to a 80% LDL reduction Can be curative if done before established
CVD; especially for HoFH
Genetic therapy Overexpression of normal LDLRs Results vary according to the applied technique Promising methods under development
FH, Familial hypercholesterolemia; HoFH, Homozygous familial hypercholesterolemia; HeFH, Heterozygous familial hypercholesterolemia; LDL, Low density lipoprotein; LP(a), lipoprotein
(a); ApoB, Apolipoprotein B; CVD, Cardiovascular disease; LDLR, Low density lipoprotein receptor; TG, Triglycerides; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A; CETP,
cholesteryl ester transfer protein; TRβ, Thyroid receptor β; MTTP, Microsomal triglyceride transfer protein; PCSK9, Proprotein convertase subtilisin/kexin type 9.
Surgical Therapy in FH
Ileal bypass and liver transplantation could be discussed as
treatment options in patients at increased CVD risk who fail to
reach the treatment targets or tolerate conventional treatment
options (Goldberg et al., 2011; Hovingh et al., 2013; Mansoorian
et al., 2015; Martinez et al., 2016).
Liver transplantation is considered a good option for HoFH
patients, as the introduction of new functional LDLRs brings the
receptor activity close to 60% and reduces LDL plasma levels
by 80%. Moreover, by restoring receptor activity, the transplant
makes it easier for statins to work on these patients (Bilheimer,
1989).
A recent study in eight pediatric HoFH patients who
underwent orthotopic liver transplantation documented an
impressive reduction in TC, LDL, Lp(a), and ApoB/ApoAI ratio,
which was maintained for 2–6 years. Notably, in the first four
of these patients, followed for 4–6 years, CAD did not develop
or progress and in fact regressed in two patients with >50%
stenosis (Martinez et al., 2016). However, aortic valve stenosis
progressed in two of the four patients, while mild hypertension
was also reported in two patients (Martinez et al., 2016). Another
similar study showed normalization of LDL levels within 1 week
after the operation (Alim et al., 2016). However, it must be noted
that in order to be curative, the procedure should be performed
before CVD is established (Alim et al., 2016; Sanna et al., 2016).
Indeed, given the lack of CHD outcome data, more such studies
are needed to evaluate the long-term efficacy of this approach
(Martinez et al., 2016). Nevertheless, this option should be offered
Frontiers in Pharmacology | www.frontiersin.org 19 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
TABLE 12 | Key points for HoFH and HeFH treatment (Goldberg et al., 2011; Catapano et al., 2016; Jellinger et al., 2017).
HoFH HeFH
• Prompt diagnosis and early initiation of aggressive treatment
• Early identification of CAD (especially ostial disease and AS)
• In addition to lifestyle, statins should be started even in receptor-negative
patients
• Combination therapy usually required (mipomersen, lomitapide, PCSK9
inhibitors)
• LA necessary in many cases
• Liver transplantation is an option if available in time
• Gene therapy seems promising, but needs more clinical trials
• Lifestyle changes should precede pharmacotherapy
• Treatment soon after diagnosis
• CVD risk factors to be addressed
• Individualized plan (specific LDL targets agreed with the patient)
• Statins as first line of treatment
• Ezetimibe as second line
• PCSK9 inhibitor could be also an adjunct if eligible
• Consider polypharmacy side effects
HoFH, Homozygous familial hypercholesterolemia; HeFH, Heterozygous familial hypercholesterolemia; LDL, Low density lipoprotein; CVD, Cardiovascular disease; CAD, Coronary artery
disease; AS, Aortic stenosis; LA, Lipoprotein apheresis; PCSK9, Proprotein convertase subtilisin/kexin type 9.
to HoFH patients who lack functional receptors completely in
order to maximize the use of the donor capacity (Bilheimer,
1989).
Moreover, a 5-year RCT in hypercholesterolemic patients with
previous premature MI (30–64 y.o.) and high cholesterol levels
showed positive results in CHD-associated mortality when diet
plus partial ileal bypass was compared to diet alone (Buchwald
et al., 1998). In addition, the 8-year follow up after partial
ileal bypass in three FH patients with xanthomas and CAD
showed a 30% reduction in cholesterol and significant change in
xanthomas, as well as CAD stabilization (Issa et al., 2000). Thus,
partial ileal bypass appears an effective treatment option for FH
patients, but more long-term studies are also needed to clarify its
safety (Moghadasian et al., 2001).
Portacaval shunt is another surgical option which can reduce
the absorption of cholesterol and enhance bile acid excretion
(Hovingh et al., 2013). This procedure is known to reduce
the rate of TC and LDL synthesis, ultimately leading to
significantly reduced plasma LDL levels in HoFH (Bilheimer
et al., 1975). Thus, this has been offered as a treatment
option to HoFH patients, but also to HeFH patients with
severe disease. However, the LDL reduction is approximately
25% in 80% of the treated patients, which is probably not
adequate for patients with extremely high LDL levels. As there
is significant residual hypercholesterolemia, the portacaval shunt
is considered to be a palliative treatment option, while liver
transplantation is considered more effective in HoFH (Bilheimer,
1989).
Overall, the existing evidence on the role of the portacaval
shunt and ileal bypass in FH treatment remains ambiguous, as
the existing literature is quite limited. In 1990, Reeves et al.
reported two patients withHoFH treated with the combination of
portacaval shunt and mammary coronary bypass grafts, showing
good long-term outcomes (Reeves et al., 1990). On the other
hand, in a more recent case report two siblings with HoFH
who underwent portacaval shunt and ileal bypass were not
spared the need for liver transplantation (Lopez-Santamaria et al.,
2000).
Gene-Targeted Therapy in FH
Genetic therapy may offer a promising approach for the
treatment of FH in the near future, since targeting specific genetic
loci may lead to precise results with minimal side effects. Indeed,
taking into account the effect on LDL clearance of introducing
healthy LDLR via liver transplantation, it seems plausible that
overexpression of normal LDLR receptors by genetic treatment
can achieve similar results (Cuchel et al., 2014b; Najam and Ray,
2015).
Viral vector-associated gene transfer can up-regulate LDLR
expression and control hypercholesterolemia in animal models
(Kassim et al., 2013; Najam and Ray, 2015). However, a pilot
study with retroviral gene transfer to hepatocytes in five HoFH
patients resulted in variable biochemical responses, highlighting
the need to establish more effective genetic treatment approaches
(Grossman et al., 1995).
Recent evidence showed that the inducible degrader of LDLR
(IDOL) constitutes a novel LDLR regulator, and prompted
the construction of LDLR variants, via specific amino acid
substitutions, which were resistant to PSCK9 and IDOL with
positive effects on LDL metabolism (Somanathan et al., 2014).
IDOL is an E3-ubiquitin ligase which binds to LDLR in a different
location than PCSK9, hence promoting receptor ubiquitination
and lysosomal degradation (Huff et al., 2014). A study on
humanized mice showed that adeno-associated virus-8 (AAV8)
mediated expression of IDOL in the liver leads to an LDLR-
dependent increase in LDL plasma levels (Ibrahim et al., 2016).
As such, further research focused on IDOL inhibitors would
be interesting. Indeed, a recent toxicology study assessing the
effects of AAV8 expressing directly LDLR in rhesus macaques
rendered the treatment safe apart from mild and transient
transaminasemia and immune adaptive responses (Greig et al.,
2017).
Moreover, AVV-induced RNA silencing methods against
ApoB (via short hairpin RNA and artificial microRNA) have
led to significant plasma cholesterol reductions (Maczuga et al.,
2014). However, substantial changes in the murine liver histology
and in genes that are implicated in cell growth, death, immune
response, and other basic cell functions have been reported
(Maczuga et al., 2014).
The regulation of ApoB splicing represents another approach
which could be applied in FH therapy. The post-transcriptional
modifications of ApoB appear to be safe and effective in
lowering cholesterol by interfering with VLDL assembly and LDL
clearance (Khoo, 2015).
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Notably, the new era in the development of transgene
expression involves advanced recombinant adenoviral vectors
which lack viral coding genes, and thus offer genetic therapy
without the adaptive immune response and the accompanying
chronic toxicity. Gene therapy with helper-dependent adenoviral
vectors (HDAd) is an example of this approach (Vetrini and
Ng, 2010). HDAd-dependent LDLR gene transport to mice has
been proven to be effective against atherosclerosis, despite its
moderate LDL-lowering effects (Li et al., 2011). For additional
anti-inflammatory effects, PEGylation techniques seem to be
useful, while this modification does not interfere with the HDAd
vector-induced LDL reduction and atherosclerosis regression
(Leggiero et al., 2013).
Rhesus macaque monkeys heterozygous for the mutant LDLR
gene (a non-human primate model of FH) have also been
tested for HDAd LDLR gene delivery (Oka et al., 2015). This
study compared intravenous injection vs. intrahepatic arterial
injection in the presence of balloon catheter-based hepatic
venous occlusion, and showed that the increased intrahepatic
pressure induced by the inhibition of the venous drainage created
an optimal environment for gene delivery in the liver. Thus, this
method requires lower doses of the viral vectors and maintains
the desirable LDL reduction (up to 59%) for a prolonged period
(Oka et al., 2015). However, this technique should be further
optimized and subsequently tested in clinical studies.
In the pursuit of an effective genetic sequence insertion
method, the Sleeping Beauty (transposon) vectors have been also
designed (Mikkelsen et al., 2003). These vectors can reach their
targets through hydrodynamic gene delivery, since a large volume
of fluid (naked DNA solution) is injected into the circulation.
Through the effect of hydrostatic pressure, this non-viral
technique amplifies endothelial and parenchymal permeability
and ultimately achieves genetic material delivery to the desired
tissues (Suda and Liu, 2007). Treatment of LDLR-deficient mice
with plasmid-based such transposon vectors demonstrated an
initial 17–19% decrease in plasma cholesterol which remained
stable. This method proved to be safe in mice, offering another
potential approach for future trials in FH patients (Turunen et al.,
2016).
In order to overcome the host-immune reactions and the
technical difficulties of non-viral genetic delivery, Hou et al.
recently demonstrated the creation of minicircle non-viral
DNA vectors (Hou et al., 2016). After specific modifications
and efficient liver-specific LDLR gene expression, correction
of hypercholesterolemia in LDLR-deficient mice was reported
without significant toxicity, thus offering another potential
genetic treatment tool against FH (Hou et al., 2016).
Furthermore, the human induced pluripotent stem cell
(hiPSC) technique has shown encouraging results via plasmid
vectors (Fattahi et al., 2013). Indeed, transformed differentiated
hepatocyte-like cells, either through vectors (Fattahi et al., 2013),
or specific genome editing via clustered-regularly-interspaced-
short-palindromic-repeats/CRISPR-associated 9 (CRISPR/Cas9)
technology, demonstrated increased LDL uptake and correction
of the FH phenotype, prompting further investigations (Omer
et al., 2017).
Recently, a study in a FH mouse model with a non-viral
vector expressing LDLR cDNA combined with a microRNA
Box 2 | Summary of pediatric FH treatment.
• Mostly similar treatment with adults
• Increased awareness required
• Not adequate clinical outcomes data due to enrolment and long-term
follow up issues
• So far, statins ± ezetimibe show promising results regarding LDL and CVD
prevention
• Treatment initiation ≤5–10 y.o. in HoFH children
• Healthy diet and exercise
• Statin initiation ≥8–10 y.o.
• LDL targets <3.5–3.6mmol/L (<135–140mg/dL) for children >10 y.o., or
at least a 50% reduction for 8–10 y.o. at very high CVD risk
HoFH, Homozygous familial hypercholesterolemia; LDL, Low density
lipoprotein; CVD, Cardiovascular disease. Consensus statements from
Wiegman et al. (2015), Catapano et al. (2016), Jellinger et al. (2017), and
Harada-Shiba et al. (2018).
which suppresses the 3-hydroxy-3-methylglutaryl-coenzyme A
reductase (Hmgcr) has also led to a 32% lipid reduction, with a
40% atherosclerotic regression in vivo after 12 weeks of treatment
(Kerr et al., 2016).
In view of these innovative techniques/approaches, more
research efforts have now focused on the development of
precise, effective and safe gene delivery strategies for the genetic
treatment of FH. These methods seem promising; however,
further research is clearly necessary in order to safely induce
effective LDLR transgene expression and ultimately achieve
sustainable LDL reductions and regression of atherosclerotic
disease in humans.
CONCLUSIONS
Presenting with variable genetic, epidemiologic and clinical
characteristics, FH is a genetic disease which is increasingly
recognized as a significant CVD risk factor that can be effectively
managed in everyday clinical practice. Table 11 summarizes the
up-to-date management of FH patients, who often remain under-
treated, whilst Table 12 further distinguishes the options for
HeFH and HoFH, and Box 2 presents the key points in pediatric
FH management. Due to the FH-related high CVD morbidity
and mortality, early prevention and effective management of
these patients is essential through organized primary care and/or
Lipid Specialist care centers. Current research further focuses on
new monoclonal antibodies/genetic targeting approaches which
may offer novel options in order to significantly lower LDL and
prevent/reduce ASCVD in FH.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
FUNDING
This work was funded by University Hospitals Coventry and
Warwickshire NHS Trust.
Frontiers in Pharmacology | www.frontiersin.org 21 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
REFERENCES
Agabiti Rosei, E., and Salvetti, M. (2016). Management of hypercholesterolemia,
appropriateness of therapeutic approaches and new drugs in patients with
high cardiovascular risk. High Blood Press. Cardiovasc. Prev. 23, 217–230.
doi: 10.1007/s40292-016-0155-2
Akdim, F., Visser, M. E., Tribble, D. L., Baker, B. F., Stroes, E. S., Yu, R., et al. (2010).
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density
lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J.
Cardiol. 105, 1413–1419. doi: 10.1016/j.amjcard.2010.01.003
Alim, A., Tokat, Y., Erdogan, Y., Gokkaya, Z., Dayangac,M., Yuzer, Y., et al. (2016).
Liver transplantation for homozygote familial hypercholesterolemia: the only
curative treatment. Pediatr. Transplant. 20, 1060–1064. doi: 10.1111/petr.12763
Alonso, R., Mata, P., Muñiz, O., Fuentes-Jimenez, F., Díaz, J. L., Zambón, D., et al.
(2016). PCSK9 and lipoprotein (a) levels are two predictors of coronary artery
calcification in asymptomatic patients with familial hypercholesterolemia.
Atherosclerosis 254, 249–253. doi: 10.1016/j.atherosclerosis.2016.08.038
Arca, M., Pigna, G., and Favoccia, C. (2012). Management of statin-intolerant
patient. Panminerva Med. 54, 105–118.
Arrieta, A., Hong, J. C., Khera, R., Virani, S. S., Krumholz, H. M.,
and Nasir, K. (2017). Updated cost-effectiveness assessments of PCSK9
inhibitors from the perspectives of the health system and private payers:
insights derived from the FOURIER trial. JAMA Cardiol. 2, 1369–1374.
doi: 10.1001/jamacardio.2017.3655
Arsenault, B. J., Perrot, N., and Couture, P. (2017). Does lifestyle contribute to
disease severity in patients with inherited lipid disorders? Curr. Opin. Lipidol.
28, 177–185. doi: 10.1097/MOL.0000000000000387
Austin, M. A., Hutter, C. M., Zimmern, R. L., and Humphries, S. E. (2004). Genetic
causes of monogenic heterozygous familial hypercholesterolemia: a HuGE
prevalence review. Am. J. Epidemiol. 160, 407–420. doi: 10.1093/aje/kwh236
Banach, M., Serban, C., Sahebkar, A., Ursoniu, S., Rysz, J., Muntner, P.,
et al. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a
meta-analysis of randomized controlled trials. Mayo Clin. Proc. 90, 24–34.
doi: 10.1016/j.mayocp.2014.08.021
Barry, A. R., O’Neill, D. E., and Graham, M. M. (2016). Primary prevention
of cardiovascular disease in older adults. Can. J. Cardiol. 32, 1074–1081.
doi: 10.1016/j.cjca.2016.01.032
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J., Komajda,
M., et al. (2007). Effects of torcetrapib in patients at high risk for coronary
events. N. Engl. J. Med. 357, 2109–2122. doi: 10.1056/NEJMoa0706628
Baum, S. J., Soffer, D., and Barton Duell, P. (2016). Emerging treatments for
heterozygous and homozygous familial hypercholesterolemia. Rev. Cardiovasc.
Med. 17, 16–27.
Bays, H. E. (2014). Lowering low-density lipoprotein cholesterol levels in
patients with type 2 diabetes mellitus. Int. J. Gen. Med. 7, 355–364.
doi: 10.2147/IJGM.S65148
Bell, D. A., and Watts, G. F. (2016). Progress in the care of
familial hypercholesterolaemia: 2016. Med. J. Aust. 205, 232–236.
doi: 10.5694/mja16.00070
Benes, L. B., Bassi, N. S., and Davidson, M. H. (2016). The risk of hepatotoxicity,
new onset diabetes and rhabdomyolysis in the era of high-intensity statin
therapy: does statin type matter? Prog. Cardiovasc. Dis. 59, 145–152.
doi: 10.1016/j.pcad.2016.08.001
Benn, M., Watts, G. F., Tybjaerg-Hansen, A., and Nordestgaard, B. G.
(2012). Familial hypercholesterolemia in the danish general population:
prevalence, coronary artery disease, and cholesterol-lowering medication. J.
Clin. Endocrinol. Metab. 97, 3956–3964. doi: 10.1210/jc.2012-1563
Berger, G. M., Miller, J. L., Bonnici, F., Joffe, H. S., and Dubovsky, D. W. (1978).
Continuous flow plasma exchange in the treatment of homozygous familial
hypercholesterolemia. Am. J. Med. 65, 243–251.
Bilen, O., and Ballantyne, C. M. (2016). Bempedoic acid (ETC-1002): an
investigational inhibitor of ATP citrate lyase. Curr. Atheroscler. Rep. 18:61.
doi: 10.1007/s11883-016-0611-4
Bilheimer, D.W. (1989). Portacaval shunt and liver transplantation in treatment of
familial hypercholesterolemia. Arteriosclerosis 9, 1158–1163.
Bilheimer, D. W., Goldstein, J. L., Grundy, S. M., and Brown, M. S. (1975).
Reduction in cholesterol and low density lipoprotein synthesis after portacaval
shunt surgery in a patient with homozygous familial hypercholesterolemia. J.
Clin. Invest. 56, 1420–1430. doi: 10.1172/JCI108223
Blom, D. J., Fayad, Z. A., Kastelein, J. J., Larrey, D., Makris, L., Schwamlein,
C., et al. (2016). LOWER, a registry of lomitapide-treated patients with
homozygous familial hypercholesterolemia: rationale and design. J. Clin.
Lipidol. 10, 273–282. doi: 10.1016/j.jacl.2015.11.011
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., et al.
(2014). A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
N. Engl. J. Med. 370, 1809–1819. doi: 10.1056/NEJMoa1316222
Bolondi, G., Mocchegiani, F., Montalti, R., Nicolini, D., Vivarelli, M., and De Pietri,
L. (2016). Predictive factors of short term outcome after liver transplantation: a
review.World J. Gastroenterol. 22, 5936–5949. doi: 10.3748/wjg.v22.i26.5936
Bos, S., Duvekot, M. H., Ten Kate, G. R., Verhoeven, A. J., Mulder, M.
T., Schinkel, A. F., et al. (2017). Carotid artery plaques and intima
medial thickness in familial hypercholesteraemic patients on long-
term statin therapy: a case control study. Atherosclerosis 256, 62–66.
doi: 10.1016/j.atherosclerosis.2016.12.005
Bouhairie, V. E., and Goldberg, A. C. (2015). Familial hypercholesterolemia.
Cardiol. Clin. 33, 169–179. doi: 10.1016/j.ccl.2015.01.001
Brænne, I., Kleinecke, M., Reiz, B., Graf, E., Strom, T., Wieland, T., et al. (2016).
Systematic analysis of variants related to familial hypercholesterolemia in
families with prematuremyocardial infarction. Eur. J. Hum. Genet. 24, 191–197.
doi: 10.1038/ejhg.2015.100
Brown, L., Rosner, B., Willett, W. W., and Sacks, F. M. (1999). Cholesterol-
lowering effects of dietary fiber: a meta-analysis. Am. J. Clin. Nutr. 69, 30–42.
doi: 10.1093/ajcn/69.1.30
Bucci, M., Tana, C., Giamberardino, M. A., and Cipollone, F. (2016). Lp(a) and
cardiovascular risk: investigating the hidden side of the moon. Nutr. Metab.
Cardiovasc. Dis. 26, 980–986 doi: 10.1016/j.numecd.2016.07.004
Buchwald, H., Varco, R. L., Boen, J. R., Williams, S. E., Hansen, B. J., Campos,
C. T., et al. (1998). Effective lipid modification by partial ileal bypass reduced
long-term coronary heart disease mortality and morbidity: five-year posttrial
follow-up report from the POSCH. Program on the Surgical Control of the
Hyperlipidemias. Arch. Intern. Med. 158, 1253–1261.
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A.,
Theroux, P., et al. (2015). Ezetimibe added to statin therapy after acute coronary
syndromes. N. Engl. J. Med. 372, 2387–2397. doi: 10.1056/NEJMoa1410489
Casula, M., Catapano, A. L., Rossi Bernardi, L., Visconti, M., and
Aronica, A. (2017). Detection of familial hypercholesterolemia in
patients from a general practice database. Atheroscler. Suppl. 29, 25–30.
doi: 10.1016/j.atherosclerosissup.2017.07.004
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J.,
Drexel, H., et al. (2016). 2016 ESC/EAS guidelines for the management of
dyslipidaemias. Eur. Heart J. 37, 2999–3058. doi: 10.1093/eurheartj/ehw272
Chan, D. C., Pang, J., Barrett, P. H., Sullivan, D. R., Mori, T. A., Burnett, J. R.,
et al. (2016). Effect of omega-3 fatty acid supplementation on arterial elasticity
in patients with familial hypercholesterolaemia on statin therapy. Nutr. Metab.
Cardiovasc. Dis. 26, 1140–1145. doi: 10.1016/j.numecd.2016.07.012
Choi, H. K., Won, E. K., and Choung, S. Y. (2016). Effect of coenzyme
Q10 supplementation in statin-treated obese rats. Biomol. Ther. (Seoul). 24,
171–177. doi: 10.4062/biomolther.2015.089
Cholesterol Treatment Trialists, C., Baigent, C., Blackwell, L., Emberson, J.,
Holland, L. E., Reith, C., et al. (2010). Efficacy and safety of more
intensive lowering of LDL cholesterol: a meta-analysis of data from
170,000 participants in 26 randomised trials. Lancet 376, 1670–1681.
doi: 10.1016/S0140-6736(10)61350-5
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., et al.
(2016). Interpretation of the evidence for the efficacy and safety of statin
therapy. Lancet 388, 2532–2561. doi: 10.1016/S0140-6736(16)31357-5
Costanzo, P., Perrone-Filardi, P., Vassallo, E., Paolillo, S., Cesarano, P., Brevetti, G.,
et al. (2010). Does carotid intima-media thickness regression predict reduction
of cardiovascular events? A meta-analysis of 41 randomized trials. J. Am. Coll.
Cardiol. 56, 2006–2020. doi: 10.1016/j.jacc.2010.05.059
Cuchel, M., Blom, D. J., and Averna, M. R. (2014a). Clinical
experience of lomitapide therapy in patients with homozygous
familial hypercholesterolaemia. Atheroscler. Suppl. 15, 33–45.
doi: 10.1016/j.atherosclerosissup.2014.07.005
Frontiers in Pharmacology | www.frontiersin.org 22 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R.
A., et al. (2014b). Homozygous familial hypercholesterolaemia: new insights
and guidance for clinicians to improve detection and clinical management. A
position paper from the Consensus Panel on Familial Hypercholesterolaemia
of the European Atherosclerosis Society. Eur. Heart J. 35, 2146–2157.
doi: 10.1093/eurheartj/ehu274
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A.
D., Hegele, R. A., et al. (2013). Efficacy and safety of a microsomal
triglyceride transfer protein inhibitor in patients with homozygous familial
hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381,
40–46. doi: 10.1016/S0140-6736(12)61731-0
de Ferranti, S. D., Rodday, A. M., Mendelson, M. M., Wong, J. B.,
Leslie, L. K., and Sheldrick, R. C. (2016). Prevalence of Familial
Hypercholesterolemia in the 1999 to 2012 United States National Health
and Nutrition Examination Surveys (NHANES). Circulation 133, 1067–1072.
doi: 10.1161/CIRCULATIONAHA.115.018791
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., and
Wierzbicki, A. S. (2017). Familial hypercholesterolaemia.Nat. Rev. Dis. Primers
3:17093. doi: 10.1038/nrdp.2017.93
deGoma, E. M., Ahmad, Z. S., O’Brien, E. C., Kindt, I., Shrader,
P., Newman, C. B., et al. (2016). Treatment gaps in adults with
heterozygous familial hypercholesterolemia in the United States: data
from the CASCADE-FH registry. Circ. Cardiovasc. Genet. 9, 240–249.
doi: 10.1161/CIRCGENETICS.116.001381
de Jesus, J. M., Kahan, S., and Eckel, R. H. (2016). Nutrition interventions
for cardiovascular disease. Med. Clin. North Am. 100, 1251–1264.
doi: 10.1016/j.mcna.2016.06.007
D’Erasmo, L., Cefalu, A. B., Noto, D., Giammanco, A., Averna, M., Pintus, P.,
et al. (2017). Efficacy of lomitapide in the treatment of familial homozygous
hypercholesterolemia: results of a real-world clinical experience in Italy. Adv.
Ther. 34, 1200–1210. doi: 10.1007/s12325-017-0531-x
Dixon, D. L., Trankle, C., Buckley, L., Parod, E., Carbone, S., Van Tassell, B. W.,
et al. (2016). A review of PCSK9 inhibition and its effects beyond LDL receptors.
J. Clin. Lipidol. 10, 1073–1080. doi: 10.1016/j.jacl.2016.07.004
Doggrell, S. A. (2018). Cardiovascular outcomes trial with anacetrapib in subjects
with high cardiovascular risk - are major benefits REVEALed? Expert Opin.
Pharmacother. 19, 611–615. doi: 10.1080/14656566.2018.1448061
Duell, P. B., Santos, R. D., Kirwan, B. A., Witztum, J. L., Tsimikas, S., and Kastelein,
J. J. (2016). Long-term mipomersen treatment is associated with a reduction
in cardiovascular events in patients with familial hypercholesterolemia. J. Clin.
Lipidol. 10, 1011–1021. doi: 10.1016/j.jacl.2016.04.013
EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz, A. J.,
Akram, A., Kondapally Seshasai, S. R., Cole, D., Watts, G. F., et al. (2016).
Pooling and expanding registries of familial hypercholesterolaemia to assess
gaps in care and improve disease management and outcomes: rationale and
design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.
Atheroscler. Suppl. 22, 1–32. doi: 10.1016/j.atherosclerosissup.2016.10.001
Eisen, A., and Giugliano, R. P. (2016). Advances in the field of proprotein
convertase subtilisin kexin type 9 inhibitors. Curr. Opin. Cardiol. 31, 644–653.
doi: 10.1097/HCO.0000000000000332
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., and Watts, G. F. (2017).
The renaissance of lipoprotein(a): brave new world for preventive cardiology?
Prog. Lipid Res. 68, 57–82. doi: 10.1016/j.plipres.2017.09.001
Ernster, L., and Dallner, G. (1995). Biochemical, physiological and medical aspects
of ubiquinone function. Biochim. Biophys. Acta 1271, 195–204.
Ershova, A. I., Meshkov, A. N., Bazhan, S. S., Storozhok, M. A., Efanov, A. Y.,
Medvedeva, I. V., et al. (2017). The prevalence of familial hypercholesterolemia
in the West Siberian region of the Russian Federation: a substudy of the
ESSE-RF. PLoS ONE 12:e0181148. doi: 10.1371/journal.pone.0181148
European Association for Cardiovascular Prevention and Rehabilitation, Reiner,
Z., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M. R., et al. (2011).
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force
for the management of dyslipidaemias of the European Society of Cardiology
(ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32,
1769–1818. doi: 10.1093/eurheartj/ehr158
Fairoozy, R. H., Futema, M., Vakili, R., Abbaszadegan, M. R., Hosseini,
S., Aminzadeh, M., et al. (2017). The genetic spectrum of Familial
Hypercholesterolemia (FH) in the Iranian population. Sci. Rep. 7:17087.
doi: 10.1038/s41598-017-17181-9
Farnier, M., Colhoun, H.M., Sasiela,W. J., Edelberg, J. M., Asset, G., and Robinson,
J. G. (2017). Long-term treatment adherence to the proprotein convertase
subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical
studies with treatment duration of 1 to 2 years. J. Clin. Lipidol. 11, 986–997.
doi: 10.1016/j.jacl.2017.05.016
Farnier, M., Gaudet, D., Valcheva, V., Minini, P., Miller, K., and Cariou, B.
(2016). Efficacy of alirocumab in high cardiovascular risk populations with
or without heterozygous familial hypercholesterolemia: pooled analysis of
eight ODYSSEY Phase 3 clinical program trials. Int. J. Cardiol. 223, 750–757.
doi: 10.1016/j.ijcard.2016.08.273
Fattahi, F., Asgari, S., Pournasr, B., Seifinejad, A., Totonchi, M., Taei,
A., et al. (2013). Disease-corrected hepatocyte-like cells from familial
hypercholesterolemia-induced pluripotent stem cells. Mol. Biotechnol. 54,
863–873. doi: 10.1007/s12033-012-9635-3
Ferdinand, K. C., and Nasser, S. A. (2015). PCSK9 inhibition: discovery, current
evidence, and potential effects on LDL-C and Lp(a). Cardiovasc. Drugs Ther.
29, 295–308. doi: 10.1007/s10557-015-6588-3
Ferrari, M., Guasti, L., Maresca, A., Mirabile, M., Contini, S., Grandi, A. M.,
et al. (2014). Association between statin-induced creatine kinase elevation
and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur. J. Clin.
Pharmacol. 70, 539–547. doi: 10.1007/s00228-014-1661-6
Filippatos, T. D., Klouras, E., Barkas, F., and Elisaf, M. (2016). Cholesteryl ester
transfer protein inhibitors: challenges and perspectives. Expert Rev. Cardiovasc.
Ther. 14, 953–962. doi: 10.1080/14779072.2016.1189327
Foody, J. M., and Vishwanath, R. (2016). Familial hypercholesterolemia/autosomal
dominant hypercholesterolemia: molecular defects, the LDL-C continuum,
and gradients of phenotypic severity. J. Clin. Lipidol. 10, 970–986.
doi: 10.1016/j.jacl.2016.04.009
France, M. (2016). Homozygous familial hypercholesterolaemia:
update on management. Paediatr. Int. Child Health. 36, 243–247.
doi: 10.1080/20469047.2016.1246640
Friday, K. E., Failor, R. A., Childs, M. T., and Bierman, E. L. (1991). Effects of n-3
and n-6 fatty acid-enriched diets on plasma lipoproteins and apolipoproteins in
heterozygous familial hypercholesterolemia. Arterioscler. Thromb. 11, 47–54.
Futema, M., Shah, S., Cooper, J. A., Li, K., Whittall, R. A., Sharifi, M., et al. (2015).
Refinement of variant selection for the LDL cholesterol genetic risk score in
the diagnosis of the polygenic form of clinical familial hypercholesterolemia
and replication in samples from 6 countries. Clin. Chem. 61, 231–238.
doi: 10.1373/clinchem.2014.231365
Gairin, D., Monard, F., Cachera, C., Bard, J. M., Amouyel, P., Duriez, P., et al.
(1990). Lipoprotein particles in homozygous familial hypercholesterolemic
patients treated with portacaval shunt and LDL apheresis. Clin. Chim. Acta.
193, 165–179.
Gallo, A., Giral, P., Carrié, A., Carreau, V., Béliard, S., Bittar, R., et al.
(2017). Early coronary calcifications are related to cholesterol burden in
heterozygous familial hypercholesterolemia. J. Clin. Lipidol. 11, 704.e2–711.e2.
doi: 10.1016/j.jacl.2017.03.016
Ganda, O. P. (2016). Statin-induced diabetes: incidence, mechanisms,
and implications. F1000Res. 5:F1000 Faculty Rev-1499.
doi: 10.12688/f1000research.8629.1
Garcia, C. K., Wilund, K., Arca, M., Zuliani, G., Fellin, R., Maioli, M.,
et al. (2001). Autosomal recessive hypercholesterolemia caused by mutations
in a putative LDL receptor adaptor protein. Science 292, 1394–1398.
doi: 10.1126/science.1060458
Gaudet, D., and Brisson, D. (2015). Gene-based therapies in lipidology:
current status and future challenges. Curr. Opin. Lipidol. 26, 553–565.
doi: 10.1097/MOL.0000000000000240
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader,
D. J., Robinson, J. G., et al. (2011). Familial hypercholesterolemia:
screening, diagnosis and management of pediatric and adult patients:
clinical guidance from the National Lipid Association Expert Panel
on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, 133–140.
doi: 10.1016/j.jacl.2011.03.001
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., andMotulsky, A. G.
(1973). Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid
Frontiers in Pharmacology | www.frontiersin.org 23 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
levels in 176 families and delineation of a new inherited disorder, combined
hyperlipidemia. J Clin Invest. 52, 1544–1568. doi: 10.1172/JCI107332
Goswami, D. S., and Manohar, T. P. (2016). Cardiometabolic risk factors in acute
coronary syndrome with special reference to non-HDL cholesterol. J. Assoc.
Physicians India. 64, 30–36.
Gouni-Berthold, I., Descamps, O. S., Fraass, U., Hartfield, E., Allcott, K., Dent,
R., et al. (2016). Systematic review of published phase 3 data on anti-PCSK9
monoclonal antibodies in patients with hypercholesterolaemia. Br. J. Clin.
Pharmacol. 82, 1412–1443. doi: 10.1111/bcp.13066
Greig, J. A., Limberis, M. P., Bell, P., Chen, S. J., Calcedo, R., Rader, D. J., et al.
(2017). Non-clinical study examining AAV8.TBG.hLDLR vector-associated
toxicity in chow-fed wild-type and LDLR+/− rhesus macaques. Hum. Gene
Ther. Clin. Dev. 28, 39–50. doi: 10.1089/humc.2017.014
Greig, S. L., andDeeks, E. D. (2016). Alirocumab: a review in hypercholesterolemia.
Am. J. Cardiovasc. Drugs 16, 141–152. doi: 10.1007/s40256-016-0166-3
Grey, A., and Bolland, M. (2014). Clinical trial evidence and
use of fish oil supplements. JAMA Intern. Med. 174, 460–462.
doi: 10.1001/jamainternmed.2013.12765
Grossman, M., Rader, D. J., Muller, D. W., Kolansky, D. M., Kozarsky, K., Clark, B.
J. III, et al. (1995). A pilot study of ex vivo gene therapy for homozygous familial
hypercholesterolaemia. Nat. Med. 1, 1148–1154.
Group, H. T. R. C., Bowman, L., Hopewell, J. C., Chen, F.,Wallendszus, K., Stevens,
W., et al. (2017). Effects of anacetrapib in patients with atherosclerotic vascular
disease. N. Engl. J. Med. 377, 1217–1227. doi: 10.1056/NEJMoa1706444
Guizoni, D. M., Dorighello, G. G., Oliveira, H. C., Delbin, M. A., Krieger,
M. H., and Davel, A. P. (2016). Aerobic exercise training protects
against endothelial dysfunction by increasing nitric oxide and hydrogen
peroxide production in LDL receptor-deficient mice. J. Transl. Med. 14:213.
doi: 10.1186/s12967-016-0972-z
Haffner, S. M., and American Diabetes, A. (2004). Dyslipidemia management
in adults with diabetes. Diabetes Care 27(Suppl. 1), S68–S71.
doi: 10.2337/diacare.27.2007.S68
Harada-Shiba, M., Arai, H., Oikawa, S., Ohta, T., Okada, T., Okamura, T., et al.
(2012a). Guidelines for the management of familial hypercholesterolemia. J.
Atheroscler. Thromb. 19, 1043–1060. doi: 10.5551/jat.14621
Harada-Shiba, M., Arai, H., Okamura, T., Yokote, K., Oikawa, S., Nohara, A., et al.
(2012b). Multicenter study to determine the diagnosis criteria of heterozygous
familial hypercholesterolemia in Japan. J. Atheroscler. Thromb. 19, 1019–1026.
doi: 10.5551/jat.14159
Harada-Shiba, M., Ohta, T., Ohtake, A., Ogura, M., Dobashi, K., Nohara, A.,
et al. (2018). Guidance for pediatric familial hypercholesterolemia 2017. J.
Atheroscler. Thromb. 25, 539–553. doi: 10.5551/jat.CR002
Haralambos, K., Ashfield-Watt, P., and McDowell, I. F. (2016). Diagnostic scoring
for familial hypercholesterolaemia in practice. Curr. Opin. Lipidol. 27, 367–374.
doi: 10.1097/MOL.0000000000000325
Hartgers, M. L., Ray, K. K., and Hovingh, G. K. (2015). New approaches in
detection and treatment of familial hypercholesterolemia. Curr. Cardiol. Rep.
17:109. doi: 10.1007/s11886-015-0665-x
Hartley, L., May, M. D., Loveman, E., Colquitt, J. L., and Rees, K. (2016). Dietary
fibre for the primary prevention of cardiovascular disease. Cochrane Database
Syst Rev. 7:CD011472. doi: 10.1002/14651858.CD011472.pub2
Health Quality Ontario (2007). Low-density lipoprotein apheresis: an evidence-
based analysis. Ont. Health Technol. Assess. Ser. 7, 1–101.
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J.,
Rader, D. J., et al. (2015). Nonstatin low-density lipoprotein-lowering therapy
and cardiovascular risk reduction-statement from ATVB council. Arterioscler.
Thromb. Vasc. Biol. 35, 2269–2280. doi: 10.1161/ATVBAHA.115.306442
Heigl, F., Hettich, R., Lotz, N., Reeg, H., Pflederer, T., Osterkorn, D., et al. (2015).
Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients
with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than
36,000 treatments at one center in Germany. Atheroscler. Suppl. 18, 154–162.
doi: 10.1016/j.atherosclerosissup.2015.02.013
Herrick, C., Bahrainy, S., and Gill, E. A. (2016). Statins and the Liver. Endocrinol.
Metab. Clin. North Am. 45, 117–128. doi: 10.1016/j.ecl.2015.09.008
Himbergen, T. M., van Tits, L. J., Voorbij, H. A., de Graaf, J., Stalenhoef,
A. F., and Roest, M. (2005). The effect of statin therapy on plasma
high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in
patients with familial hypercholesterolaemia. J. Intern. Med. 258, 442–449.
doi: 10.1111/j.1365-2796.2005.01557.x
Holbrook, A., Wright, M., Sung, M., Ribic, C., and Baker, S. (2011). Statin-
associated rhabdomyolysis: is there a dose-response relationship? Can. J.
Cardiol. 27, 146–151. doi: 10.1016/j.cjca.2010.12.024
Hou, X., Jiao, R., Guo, X., Wang, T., Chen, P., Wang, D., et al. (2016). Construction
of minicircle DNA vectors capable of correcting familial hypercholesterolemia
phenotype in a LDLR-deficient mouse model. Gene Ther. 23, 657–663.
doi: 10.1038/gt.2016.37
Hovingh, G. K., Davidson, M. H., Kastelein, J. J., and O’Connor, A. M. (2013).
Diagnosis and treatment of familial hypercholesterolaemia. Eur. Heart J. 34,
962–971. doi: 10.1093/eurheartj/eht015
Hovingh, G. K., Kastelein, J. J., van Deventer, S. J., Round, P., Ford, J.,
Saleheen, D., et al. (2015a). Cholesterol ester transfer protein inhibition
by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised,
double-blind, placebo-controlled phase 2 trial. Lancet 386, 452–460.
doi: 10.1016/S0140-6736(15)60158-1
Hovingh, G. K., Smits, L. P., Stefanutti, C., Soran, H., Kwok, S., de Graaf,
J., et al. (2015b). The effect of an apolipoprotein A-I-containing high-
density lipoprotein-mimetic particle (CER-001) on carotid artery wall
thickness in patients with homozygous familial hypercholesterolemia: the
Modifying Orphan Disease Evaluation (MODE) study. Am. Heart J. 169,
736.e731–742.e731. doi: 10.1016/j.ahj.2015.01.008
Huang, B., Svensson, P., Arnlov, J., Sundstrom, J., Lind, L., and Ingelsson,
E. (2016). Effects of cigarette smoking on cardiovascular-related protein
profiles in two community-based cohort studies. Atherosclerosis 254, 52–58.
doi: 10.1016/j.atherosclerosis.2016.09.014
Huff, M. W., Assini, J. M., and Hegele, R. A. (2014). Gene therapy for
hypercholesterolemia: sweet dreams and flying machines. Circ. Res. 115,
542–545. doi: 10.1161/CIRCRESAHA.114.304800
Hutter, C. M., Austin, M. A., and Humphries, S. E. (2004). Familial
hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE
minireview. Am. J. Epidemiol. 160, 430–435. doi: 10.1093/aje/kwh238
Ibrahim, S., Somanathan, S., Billheimer, J., Wilson, J. M., and Rader, D. J. (2016).
Stable liver-specific expression of human IDOL in humanized mice raises
plasma cholesterol. Cardiovasc. Res. 110, 23–29. doi: 10.1093/cvr/cvw010
Issa, J. S., Garrido, A. Jr., Giannini, S. D., Forti, N., Diament, J., and Pinotti, H.
W. (2000). Clinical outcome of patients with familial hypercholesterolemia
and coronary artery disease undergoing partial ileal bypass surgery. Arq. Bras.
Cardiol. 75, 49–58. doi: 10.1590/S0066-782X2000000700005
Ito,M. K., and Santos, R. D. (2016). PCSK9 inhibition withmonoclonal antibodies-
modern management of hypercholesterolemia. J. Clin. Pharmacol. 57, 7–32.
doi: 10.1002/jcph.766
Ito, M. K., and Watts, G. F. (2015). Challenges in the diagnosis and
treatment of homozygous familial hypercholesterolemia. Drugs 75, 1715–1724.
doi: 10.1007/s40265-015-0466-y
Jacobson, T. A. (2013). Lipoprotein(a), cardiovascular disease, and
contemporary management. Mayo Clin. Proc. 88, 1294–1311.
doi: 10.1016/j.mayocp.2013.09.003
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca,
V. A., Garber, A. J., et al. (2017). American Association of Clinical
Endocrinologists and American College of Endocrinology Guidelines for
Management of Dyslipidemia and Prevention of Cardiovascular Disease.
Endocr. Pract. 23, 1–87. doi: 10.4158/EP171764.APPGL
Jones, P. H., Bays, H. E., Chaudhari, U., Pordy, R., Lorenzato, C.,
Miller, K., et al. (2016). Safety of Alirocumab (A PCSK9 monoclonal
antibody) from 14 randomized trials. Am. J. Cardiol. 118, 1805–1811.
doi: 10.1016/j.amjcard.2016.08.072
Kalina, A., Csaszar, A., Czeizel, A. E., Romics, L., Szaboki, F., Szalai, C., et al.
(2001). Frequency of the R3500Q mutation of the apolipoprotein B-100 gene
in a sample screened clinically for familial hypercholesterolemia in Hungary.
Atherosclerosis 154, 247–251. doi: 10.1016/S0021-9150(00)00648-1
Kassim, S. H., Li, H., Bell, P., Somanathan, S., Lagor, W., Jacobs, F., et al. (2013).
Adeno-associated virus serotype 8 gene therapy leads to significant lowering
of plasma cholesterol levels in humanized mouse models of homozygous
and heterozygous familial hypercholesterolemia. Hum. Gene Ther. 24, 19–26.
doi: 10.1089/hum.2012.108
Frontiers in Pharmacology | www.frontiersin.org 24 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
Kastelein, J. J., Besseling, J., Shah, S., Bergeron, J., Langslet, G., Hovingh,
G. K., et al. (2015). Anacetrapib as lipid-modifying therapy in patients
with heterozygous familial hypercholesterolaemia (REALIZE): a randomised,
double-blind, placebo-controlled, phase 3 study. Lancet 385, 2153–2161.
doi: 10.1016/S0140-6736(14)62115-2
Kastelein, J. J., Nissen, S. E., Rader, D. J., Hovingh, G. K., Wang, M. D.,
Shen, T., et al. (2016). Safety and efficacy of LY3015014, a monoclonal
antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a
randomized, placebo-controlled Phase 2 study. Eur. Heart J. 37, 1360–1369.
doi: 10.1093/eurheartj/ehv707
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson,
S. D., et al. (2016). Cost-effectiveness of PCSK9 Inhibitor Therapy in
Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic
Cardiovascular Disease. JAMA 316, 743–753. doi: 10.1001/jama.2016.11004
Kerr, A. G., Tam, L. C., Hale, A. B., Cioroch, M., Douglas, G., Channon, K.
M., et al. (2016). Episomal nonviral gene therapy vectors slow progression of
atherosclerosis in a model of familial hypercholesterolemia.Mol. Ther. Nucleic
Acids 5:e383. doi: 10.1038/mtna.2016.86
Kerr, M., Pears, R., Miedzybrodzka, Z., Haralambos, K., Cather, M., Watson,
M., et al. (2017). Cost effectiveness of cascade testing for familial
hypercholesterolaemia, based on data from familial hypercholesterolaemia
services in the UK. Eur. Heart J. 38, 1832–1839. doi: 10.1093/eurheartj/ehx111
Khan, S. P., Ahmed, K. Z., Yaqub, Z., and Ghani, R. (2011). Carotid intima-
media thickness correlation with lipid profile in patients with familial
hypercholesterolemia versus controls. J. Coll. Physicians Surg. Pak. 21, 30–33.
Khera, A. V., Won, H. H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng,
X., et al. (2016). Diagnostic yield and clinical utility of sequencing familial
hypercholesterolemia genes in patients with severe hypercholesterolemia. J.
Am. Coll. Cardiol. 67, 2578–2589. doi: 10.1016/j.jacc.2016.03.520
Khoo, B. (2015). Genetic therapies to lower cholesterol. Vascul. Pharmacol. 64,
11–15. doi: 10.1016/j.vph.2014.12.002
Kim, Y. R., and Han, K. H. (2013). Familial hypercholesterolemia
and the atherosclerotic disease. Korean Circ. J. 43, 363–367.
doi: 10.4070/kcj.2013.43.6.363
Knickelbine, T., Lui, M., Garberich, R., Miedema, M. D., Strauss, C., and
VanWormer, J. J. (2016). Familial hypercholesterolemia in a large
ambulatory population: statin use, optimal treatment, and identification
for advanced medical therapies. J. Clin. Lipidol. 10, 1182–1187.
doi: 10.1016/j.jacl.2016.05.007
Kolansky, D. M., Cuchel, M., Clark, B. J., Paridon, S., McCrindle, B. W., Wiegers,
S. E., et al. (2008). Longitudinal evaluation and assessment of cardiovascular
disease in patients with homozygous familial hypercholesterolemia. Am. J.
Cardiol. 102, 1438–1443. doi: 10.1016/j.amjcard.2008.07.035
Kootte, R. S., Smits, L. P., van der Valk, F. M., Dasseux, J. L., Keyserling, C. H.,
Barbaras, R., et al. (2015). Effect of open-label infusion of an apoA-I-containing
particle (CER-001) on RCT and artery wall thickness in patients with FHA. J.
Lipid Res. 56, 703–712. doi: 10.1194/jlr.M055665
Korman, M., and Wisloff, T. (2018). Modelling the cost-effectiveness of PCSK9
inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Eur.
Heart J. Cardiovasc. Pharmacother. 4, 15–22. doi: 10.1093/ehjcvp/pvx010
Kraehling, J. R., Chidlow, J. H., Rajagopal, C., Sugiyama, M. G., Fowler, J. W.,
Lee, M. Y., et al. (2016). Genome-wide RNAi screen reveals ALK1 mediates
LDL uptake and transcytosis in endothelial cells. Nat. Commun. 7:13516.
doi: 10.1038/ncomms13516
Krahenbuhl, S., Pavik-Mezzour, I., and von Eckardstein, A. (2016). Unmet
needs in LDL-C lowering: when statins won’t do! Drugs. 76, 1175–1190.
doi: 10.1007/s40265-016-0613-0
Lahtinen, A. M., Havulinna, A. S., Jula, A., Salomaa, V., and Kontula, K.
(2015). Prevalence and clinical correlates of familial hypercholesterolemia
founder mutations in the general population. Atherosclerosis 238, 64–69.
doi: 10.1016/j.atherosclerosis.2014.11.015
Lammel Lindemann, J., and Webb, P. (2016). Sobetirome: the past, present
and questions about the future. Expert Opin. Ther. Targets 20, 145–149.
doi: 10.1517/14728222.2016.1090429
Landmesser, U., Chapman, M. J., Farnier, M., Gencer, B., Gielen, S.,
Hovingh, G. K., et al. (2017a). European Society of Cardiology/European
Atherosclerosis Society Task Force consensus statement on proprotein
convertase subtilisin/kexin type 9 inhibitors: practical guidance for use
in patients at very high cardiovascular risk. Eur. Heart J. 38, 2245–2255.
doi: 10.1093/eurheartj/ehw480
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Boren, J.,
et al. (2017b). 2017 update of ESC/EAS Task Force on practical clinical guidance
for proprotein convertase subtilisin/kexin type 9 inhibition in patients with
atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
Eur. Heart J. 39, 1131–1143. doi: 10.1093/eurheartj/ehx549
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F.,
Boren, J., et al. (2018). New prospects for PCSK9 inhibition? Eur. Heart J.
doi: 10.1093/eurheartj/ehy147. [Epub ahead of print].
Lappegard, K. T., Enebakk, T., Thunhaug, H., and Hovland, A. (2016). Transition
from LDL apheresis to evolocumab in heterozygous FH is equally effective in
lowering LDL, without lowering HDL cholesterol.Atherosclerosis 251, 119–123.
doi: 10.1016/j.atherosclerosis.2016.06.015
Latkovskis, G., Saripo, V., Sokolova, E., Upite, D., Vanaga, I., Kletnieks, U., et al.
(2016). Pilot study of safety and efficacy of polyprenols in combination with
coenzyme Q10 in patients with statin-induced myopathy. Medicina (Kaunas)
52, 171–179. doi: 10.1016/j.medici.2016.05.002
Lee, M., Saver, J. L., Towfighi, A., Chow, J., and Ovbiagele, B. (2011).
Efficacy of fibrates for cardiovascular risk reduction in persons with
atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 217, 492–498.
doi: 10.1016/j.atherosclerosis.2011.04.020
Leggiero, E., Astone, D., Cerullo, V., Lombardo, B., Mazzaccara, C., Labruna, G.,
et al. (2013). PEGylated helper-dependent adenoviral vector expressing human
Apo A-I for gene therapy in LDLR-deficient mice. Gene Ther. 20, 1124–1130.
doi: 10.1038/gt.2013.38
Li, R., Chao, H., Ko, K. W., Cormier, S., Dieker, C., Nour, E. A., et al. (2011). Gene
therapy targeting LDL cholesterol but not HDL cholesterol induces regression
of advanced atherosclerosis in a mouse model of familial hypercholesterolemia.
J. Genet. Syndr. Gene Ther. 2:106. doi: 10.4172/2157-7412.1000106
Lin, J. Z., Martagon, A. J., Hsueh, W. A., Baxter, J. D., Gustafsson, J. A.,
Webb, P., et al. (2012). Thyroid hormone receptor agonists reduce serum
cholesterol independent of the LDL receptor. Endocrinology 153, 6136–6144.
doi: 10.1210/en.2011-2081
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D.
D. Jr., DePalma, S. M., et al. (2017). 2017 Focused update of the 2016 ACC
expert consensus decision pathway on the role of non-statin therapies for
LDL-cholesterol lowering in the management of atherosclerotic cardiovascular
disease risk: a report of the American college of cardiology task force on
expert consensus decision pathways. J. Am. Coll. Cardiol. 70, 1785–1822.
doi: 10.1016/j.jacc.2017.07.745
Lopez-Santamaria, M., Migliazza, L., Gamez, M., Murcia, J., Diaz-Gonzalez,
M., Camarena, C., et al. (2000). Liver transplantation in patients with
homozygotic familial hypercholesterolemia previously treated by end-to-
side portocaval shunt and ileal bypass. J. Pediatr. Surg. 35, 630–633.
doi: 10.1053/jpsu.2000.0350630
Lozano, P., Henrikson, N. B., Dunn, J., Morrison, C. C., Nguyen, M., Blasi,
P. R., et al. (2016). Lipid screening in childhood and adolescence for
detection of familial hypercholesterolemia: evidence report and systematic
review for the US Preventive Services Task Force. JAMA 316, 645–655.
doi: 10.1001/jama.2016.6176
Lupien, P. J., Moorjani, S., and Awad, J. (1976). A new approach to the
management of familial hypercholesterolaemia: removal of plasma-cholesterol
based on the principle of affinity chromatography. Lancet 1, 1261–1265.
Mabuchi, H., Haba, T., Ueda, K., Ueda, R., Tatami, R., Ito, S., et al. (1977). Serum
lipids and coronary heart disease in heterozygous familial hypercholesterolemia
in the Hokuriku District of Japan. Atherosclerosis 28, 417–423.
Maczuga, P., Verheij, J., van der Loos, C., van Logtenstein, R., Hooijer, G., Martier,
R., et al. (2014). Therapeutic expression of hairpins targeting apolipoprotein
B100 induces phenotypic and transcriptome changes in murine liver. Gene
Ther. 21, 60–70. doi: 10.1038/gt.2013.58
Maki, K. C., Dicklin, M. R., and Baum, S. J. (2016). Statins and Diabetes.
Endocrinol. Metab. Clin. North Am. 45, 87–100. doi: 10.1016/j.ecl.
2015.09.006
Malhotra, A., Shafiq, N., Arora, A., Singh, M., Kumar, R., and Malhotra, S. (2014).
Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein
and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst.
Rev. 10:CD001918. doi: 10.1002/14651858.CD001918.pub3
Frontiers in Pharmacology | www.frontiersin.org 25 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
Mansoorian, M., Kazemi, K., Nikeghbalian, S., Shamsaeefar, A., Mokhtari, M.,
Dehghani, S. M., et al. (2015). Liver transplantation as a definitive treatment
for familial hypercholesterolemia: a series of 36 cases. Pediatr. Transplant. 19,
605–611. doi: 10.1111/petr.12562
Martinez, M., Brodlie, S., Griesemer, A., Kato, T., Harren, P., Gordon, B., et al.
(2016). Effects of liver transplantation on lipids and cardiovascular disease in
children with homozygous familial hypercholesterolemia. Am. J. Cardiol. 118,
504–510. doi: 10.1016/j.amjcard.2016.05.042
McLain, J. H., Alsterda, A. J., and Arora, R. R. (2016). Cholesteryl ester transfer
protein inhibitors: trials and tribulations. J. Cardiovasc. Pharmacol. Ther.
doi: 10.1177/1074248416662349
McPherson, R., and Hegele, R. A. (2015). Ezetimibe: rescued by randomization
(clinical and mendelian). Arterioscler. Thromb. Vasc. Biol. 35, e13–e15.
doi: 10.1161/ATVBAHA.114.305012
Miedema, M. D., and Virani, S. S. (2016). Harder-to-treat patients: recognizing
them and adapting treatment strategies. Am. J. Cardiol. 118, 13A−18A.
doi: 10.1016/j.amjcard.2016.05.027
Migliara, G., Baccolini, V., Rosso, A., D’Andrea, E., Massimi, A., Villari, P.,
et al. (2017). Familial hypercholesterolemia: a systematic review of guidelines
on genetic testing and patient management. Front. Public Health. 5:252.
doi: 10.3389/fpubh.2017.00252
Mikkelsen, J. G., Yant, S. R., Meuse, L., Huang, Z., Xu, H., and Kay, M. A.
(2003). Helper-independent sleeping beauty transposon-transposase vectors for
efficient nonviral gene delivery and persistent gene expression in vivo. Mol.
Ther. 8, 654–665. doi: 10.1016/S1525-0016(03)00216-8
Moghadasian, M. H., Frohlich, J. J., Saleem, M., Hong, J. M., Qayumi, K.,
and Scudamore, C. H. (2001). Surgical management of dyslipidemia:
clinical and experimental evidence. J. Invest. Surg. 14, 71–78.
doi: 10.1080/08941930152024183
Moorjani, S., Roy, M., Gagne, C., Davignon, J., Brun, D., Toussaint, M., et al.
(1989). Homozygous familial hypercholesterolemia among French Canadians
in Quebec Province. Arteriosclerosis 9, 211–216.
Moriarty, P. M., and Hemphill, L. (2016). Lipoprotein apheresis. Endocrinol.
Metab. Clin. North Am. 45, 39–54. doi: 10.1016/j.ecl.2015.09.003
Moriarty, P. M., Parhofer, K. G., Babirak, S. P., Cornier, M. A., Duell, P. B.,
Hohenstein, B., et al. (2016). Alirocumab in patients with heterozygous familial
hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY
ESCAPE trial. Eur. Heart J. 37, 3588–3595. doi: 10.1093/eurheartj/ehw388
Myocardial Infarction Genetics Consortium, I., Stitziel, N. O., Won, H. H.,
Morrison, A. C., Peloso, G. M., Do, R., et al. (2014). Inactivating mutations
in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 371,
2072–2082. doi: 10.1056/NEJMoa1405386
Najam, O., and Ray, K. K. (2015). Familial hypercholesterolemia: a review of
the natural history, diagnosis, and management. Cardiol Ther. 4, 25–38.
doi: 10.1007/s40119-015-0037-z
Narverud, I., van Lennep, J. R., Christensen, J. J., Versmissen, J., Gran, J. M.,
Iversen, P. O., et al. (2015). Maternal inheritance does not predict cholesterol
levels in children with familial hypercholesterolemia. Atherosclerosis 243,
155–160. doi: 10.1016/j.atherosclerosis.2015.09.014
National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) (2002). Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
final report. Circulation 106, 3143–3421.
Navarese, E. P., Kolodziejczak, M., Dimitroulis, D., Wolff, G., Busch, H. L., Devito,
F., et al. (2016). From proprotein convertase subtilisin/kexin type 9 to its
inhibition: state-of-the-art and clinical implications. Eur. Heart J. Cardiovasc.
Pharmacother. 2, 44–53. doi: 10.1093/ehjcvp/pvv045
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., et al.
(2008). Reductions in all-cause, cancer, and coronary mortality in statin-treated
patients with heterozygous familial hypercholesterolaemia: a prospective
registry study. Eur. Heart J. 29, 2625–2633. doi: 10.1093/eurheartj/ehn422
Nelson, K. L., Stenehjem, D., Driscoll, M., and Gilcrease, G.W. (2017). Fatal statin-
induced rhabdomyolysis by possible interaction with palbociclib. Front. Oncol.
7:150. doi: 10.3389/fonc.2017.00150
Nicholls, S. J., Ruotolo, G., Brewer, H. B., Wang, M. D., Liu, L., Willey, M. B., et al.
(2016). Evacetrapib alone or in combination with statins lowers lipoprotein(a)
and total and small LDL particle concentrations in mildly hypercholesterolemic
patients. J. Clin. Lipidol. 10, 519.e514–527.e514. doi: 10.1016/j.jacl.
2015.11.014
Noordally, S. O., Sohawon, S., Vanderhulst, J., Duttmann, R., Corazza, F., and
Devriendt, J. (2012). A fatal case of cutaneous adverse drug-induced toxic
epidermal necrolysis associated with severe rhabdomyolysis. Ann. Saudi Med.
32, 309–311. doi: 10.5144/0256-4947.2012.309
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N.,
Masana, L., Descamps, O. S., et al. (2013). Familial hypercholesterolaemia
is underdiagnosed and undertreated in the general population: guidance
for clinicians to prevent coronary heart disease: consensus statement of
the European Atherosclerosis Society. Eur. Heart J. 34, 3478a−3490a.
doi: 10.1093/eurheartj/eht273
Nussbaumer, B., Glechner, A., Kaminski-Hartenthaler, A., Mahlknecht, P., and
Gartlehner, G. (2016). Ezetimibe-statin combination therapy. Dtsch. Arztebl.
Int. 113, 445–453. doi: 10.3238/arztebl.2016.0445
Ohmura, H., Fukushima, Y., Mizuno, A., Niwa, K., Kobayashi, Y., Ebina, T., et al.
(2017). Estimated prevalence of heterozygous familial hypercholesterolemia
in patients with acute coronary syndrome. Int. Heart J. 58, 88–94.
doi: 10.1536/ihj.16-188
Oka, K., Mullins, C. E., Kushwaha, R. S., Leen, A. M., and Chan, L. (2015).
Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by
balloon catheter hepatic delivery of helper-dependent adenoviral vector. Gene
Ther. 22, 87–95. doi: 10.1038/gt.2014.85
Omer, L., Hudson, E. A., Zheng, S., Hoying, J. B., Shan, Y., and Boyd, N. L.
(2017). CRISPR correction of a homozygous low-density lipoprotein receptor
mutation in familial hypercholesterolemia induced pluripotent stem cells.
Hepatol. Commun. 1, 886–898. doi: 10.1002/hep4.1110
Ooi, E. M., Barrett, P. H., and Watts, G. F. (2013). The extended abnormalities
in lipoprotein metabolism in familial hypercholesterolemia: developing a
new framework for future therapies. Int. J. Cardiol. 168, 1811–1818.
doi: 10.1016/j.ijcard.2013.06.069
Orringer, C. E., Jacobson, T. A., Saseen, J. J., Brown, A. S., Gotto, A. M.,
Ross, J. L., et al. (2017). Update on the use of PCSK9 inhibitors in adults:
recommendations from an Expert Panel of the National Lipid Association. J.
Clin. Lipidol. doi: 10.1016/j.jacl.2017.05.001
Pang, J., Martin, A. C., Mori, T. A., Beilin, L. J., andWatts, G. F. (2016). Prevalence
of familial hypercholesterolemia in adolescents: potential value of universal
screening? J. Pediatr. 170, 315–316. doi: 10.1016/j.jpeds.2015.11.019
Paquette, M., Dufour, R., and Baass, A. (2017a). The Montreal-FH-SCORE: a new
score to predict cardiovascular events in familial hypercholesterolemia. J. Clin.
Lipidol. 11, 80–86. doi: 10.1016/j.jacl.2016.10.004
Paquette, M., Dufour, R., and Baass, A. (2017b). Scavenger receptor
LOX1 genotype predicts coronary artery disease in patients with
familial hypercholesterolemia. Can. J. Cardiol. 33, 1312–1318.
doi: 10.1016/j.cjca.2017.07.480
Parente, F., Vesnaver, M., Massie, R., and Baass, A. (2016). An unusual
cause of Achilles tendon xanthoma. J. Clin. Lipidol. 10, 1040–1044.
doi: 10.1016/j.jacl.2016.05.001
Parihar, R. K., Razaq, M., and Saini, G. (2012). Homozygous familial
hypercholesterolemia. Indian J. Endocrinol. Metab. 16, 643–645.
doi: 10.4103/2230-8210.98032
Pase, M. P., Grima, N. A., and Sarris, J. (2011). Do long-chain n-3 fatty acids reduce
arterial stiffness? A meta-analysis of randomised controlled trials. Br. J. Nutr.
106, 974–980. doi: 10.1017/S0007114511002819
Pasternak, R. C., Smith, S. C. Jr., Bairey-Merz, C. N., Grundy, S. M.,
Cleeman, J. I., Lenfant, C., et al. (2002). ACC/AHA/NHLBI clinical
advisory on the use and safety of statins. Circulation 106, 1024–1028.
doi: 10.1161/01.CIR.0000032466.44170.44
Patel, R. S., Scopelliti, E. M., and Savelloni, J. (2015). Therapeutic management
of familial hypercholesterolemia: current and emerging drug therapies.
Pharmacotherapy 35, 1189–1203. doi: 10.1002/phar.1672
Penson, P., McGowan, M., and Banach, M. (2017). Evaluating bempedoic acid for
the treatment of hyperlipidaemia. Expert Opin. Investig. Drugs. 26, 251–259.
doi: 10.1080/13543784.2017.1280458
Perez de Isla, L., Alonso, R., Mata, N., Saltijeral, A., Muniz, O., Rubio-Marin, P.,
et al. (2016). Coronary heart disease, peripheral arterial disease, and stroke
in familial hypercholesterolaemia: insights from the SAFEHEART Registry
Frontiers in Pharmacology | www.frontiersin.org 26 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
(Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler. Thromb.
Vasc. Biol. 36, 2004–2010. doi: 10.1161/ATVBAHA.116.307514
Perry, C. M. (2010). Colesevelam: in pediatric patients with heterozygous
familial hypercholesterolemia. Paediatr. Drugs 12, 133–140.
doi: 10.2165/11204890-000000000-00000
Phan, B. A., Moore, A. B., Davis, J., Pollan, L. J., Neradilek, B., Brown, B. G.,
et al. (2014). Prolonged combination lipid therapy is associated with reduced
carotid intima-media thickness: a case-control study of the 20-year Familial
Atherosclerosis Treatment-Observational Study (FATS-OS). J. Clin. Lipidol. 8,
489–493. doi: 10.1016/j.jacl.2014.07.004
Pijlman, A. H., Huijgen, R., Verhagen, S. N., Imholz, B. P., Liem, A. H., Kastelein,
J. J., et al. (2010). Evaluation of cholesterol lowering treatment of patients with
familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
Atherosclerosis 209, 189–194. doi: 10.1016/j.atherosclerosis.2009.09.014
Pirillo, A., Garlaschelli, K., Arca, M., Averna, M., Bertolini, S., Calandra,
S., et al. (2017). Spectrum of mutations in Italian patients with familial
hypercholesterolemia: new results from the LIPIGEN study. Atheroscler. Suppl.
29, 17–24. doi: 10.1016/j.atherosclerosissup.2017.07.002
Plosker, G. L., and Lyseng-Williamson, K. A. (2007). Atorvastatin: a
pharmacoeconomic review of its use in the primary and secondary
prevention of cardiovascular events. Pharmacoeconomics 25, 1031–1053.
doi: 10.2165/00019053-200725120-00005
Postmus, I., Warren, H. R., Trompet, S., Arsenault, B. J., Avery, C. L.,
Bis, J. C., et al. (2016). Meta-analysis of genome-wide association studies
of HDL cholesterol response to statins. J. Med. Genet. 53, 835–845.
doi: 10.1136/jmedgenet-2016-103966
Qian, L. J., Gao, Y., Zhang, Y. M., Chu, M., Yao, J., and Xu, D. (2017).
Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial
hypercholesterolemia and statin-intolerant patients: a meta-analysis of 15
randomized controlled trials. Sci. Rep. 7:238. doi: 10.1038/s41598-017-00316-3
Raal, F. J., Braamskamp, M. J., Selvey, S. L., Sensinger, C. H., and Kastelein,
J. J. (2016a). Pediatric experience with mipomersen as adjunctive therapy
for homozygous familial hypercholesterolemia. J. Clin. Lipidol. 10, 860–869.
doi: 10.1016/j.jacl.2016.02.018
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M. J., Cromwell, W. C.,
et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering
of LDL cholesterol concentrations in patients with homozygous familial
hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Lancet 375, 998–1006. doi: 10.1016/S0140-6736(10)60284-X
Raal, F. J., Sjouke, B., Hovingh, G. K., and Isaac, B. F. (2016b). Phenotype diversity
among patients with homozygous familial hypercholesterolemia: a cohort
study. Atherosclerosis 248, 238–244. doi: 10.1016/j.atherosclerosis.2016.03.009
Rader, D. J., Cohen, J., and Hobbs, H. H. (2003). Monogenic hypercholesterolemia:
new insights in pathogenesis and treatment. J. Clin. Invest. 111, 1795–1803.
doi: 10.1172/JCI18925
Rahal, A. J., ElMallah, A. I., Poushuju, R. J., and Itani, R. (2016). Do statins really
cause diabetes? A meta-analysis of major randomized controlled clinical trials.
Saudi Med. J. 37, 1051–1060. doi: 10.15537/smj.2016.10.16078
Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini,
P., et al. (2016). Reductions in atherogenic lipids and major cardiovascular
events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with
control. Circulation 134, 1931–1943. doi: 10.1161/CIRCULATIONAHA.116.
024604
Reeves, F., Gosselin, G., Hebert, Y., and Lambert, M. (1990). Long term follow-
up after portacaval shunt and internal mammary coronary bypass graft in
homozygous familial hypercholesterolemia: report of two cases. Can. J. Cardiol.
6, 171–174.
Reiman, A., Pandey, S., Lloyd, K. L., Dyer, N., Khan, M., Crockard, M., et al. (2016).
Molecular testing for familial hypercholesterolaemia-associated mutations in a
UK-based cohort: development of an NGS-based method and comparison with
multiplex polymerase chain reaction and oligonucleotide arrays. Ann. Clin.
Biochem. 53, 654–662. doi: 10.1177/0004563216629170
Reiner, Z. (2015). Management of patients with familial hypercholesterolaemia.
Nat. Rev. Cardiol. 12, 565–575. doi: 10.1038/nrcardio.2015.92
Ridker, P. M., Amarenco, P., Brunell, R., Glynn, R. J., Jukema, J. W., Kastelein,
J. J., et al. (2016). Evaluating bococizumab, a monoclonal antibody to
PCSK9, on lipid levels and clinical events in broad patient groups with
and without prior cardiovascular events: rationale and design of the Studies
of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) lipid
lowering and SPIRE cardiovascular outcomes trials. Am. Heart J. 178, 135–144.
doi: 10.1016/j.ahj.2016.05.010
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., et al.
(2017a). cardiovascular efficacy and safety of bococizumab in high-risk patients.
N. Engl. J. Med. 376, 1527–1539. doi: 10.1056/NEJMoa1701488
Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J.,
Jukema, J. W., et al. (2017b). Lipid-reduction variability and antidrug-
antibody formation with bococizumab. N. Engl. J. Med. 376, 1517–1526.
doi: 10.1056/NEJMoa1614062
Robinson, D. M., and Keating, G. M. (2007). Colesevelam: a review of
its use in hypercholesterolemia. Am. J. Cardiovasc. Drugs. 7, 453–465.
doi: 10.2165/00129784-200707060-00009
Roeters van Lennep, J., Averna, M., and Alonso, R. (2015). Treating homozygous
familial hypercholesterolemia in a real-world setting: experiences with
lomitapide. J. Clin. Lipidol. 9, 607–617. doi: 10.1016/j.jacl.2015.05.001
Rojas-Fernandez, C., Hudani, Z., and Bittner, V. (2016). Statins and cognitive side
effects: what cardiologists need to know. Endocrinol. Metab. Clin. North Am.
45, 101–116. doi: 10.1016/j.ecl.2015.09.007
Romagnuolo, R., Scipione, C. A., Boffa, M. B., Marcovina, S. M., Seidah, N. G., and
Koschinsky, M. L. (2015). Lipoprotein(a) catabolism is regulated by proprotein
convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
J. Biol. Chem. 290, 11649–11662. doi: 10.1074/jbc.M114.611988
Rust, P., and Ekmekcioglu, C. (2016). Impact of salt intake on the pathogenesis
and treatment of hypertension. Adv. Exp. Med. Biol. 956, 61–84.
doi: 10.1007/55842016147
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott,
S. D., Murphy, S. A., et al. (2017). Evolocumab and clinical outcomes
in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722.
doi: 10.1056/NEJMoa1615664
Sabatine, M. S., Underberg, J. A., Koren, M., and Baum, S. J. (2016). Focus on
PCSK9 inhibitors: from genetics to clinical practice. Postgrad. Med. 128(Suppl
1), 31–39. doi: 10.1080/00325481.2016.1208895
Safarova, M. S., Liu, H., and Kullo, I. J. (2016). Rapid identification of familial
hypercholesterolemia from electronic health records: the SEARCH study. J.
Clin. Lipidol. 10, 1230–1239. doi: 10.1016/j.jacl.2016.08.001
Saha, S. P., and Whayne, T. F. Jr. (2016). Coenzyme Q-10 in
human health: supporting evidence? South. Med. J. 109, 17–21.
doi: 10.14423/SMJ.0000000000000393
Sala-Vila, A., Cofan, M., Mateo-Gallego, R., Cenarro, A., Civeira, F., and Ros,
E. (2013). Eicosapentaenoic acid in serum phospholipids relates to a less
atherogenic lipoprotein profile in subjects with familial hypercholesterolemia.
J. Nutr. Biochem. 24, 1604–1608. doi: 10.1016/j.jnutbio.2013.01.011
Samaras, K., Brodaty, H., and Sachdev, P. S. (2016). Does statin use cause
memory decline in the elderly? Trends Cardiovasc. Med. 26, 550–565.
doi: 10.1016/j.tcm.2016.03.009
Sanchez-Hernandez, R. M., Civeira, F., Stef, M., Perez-Calahorra, S., Almagro, F.,
Plana, N., et al. (2016). Homozygous familial hypercholesterolemia in spain:
prevalence and phenotype-genotype relationship. Circ. Cardiovasc. Genet. 9,
504–510. doi: 10.1161/CIRCGENETICS.116.001545
Sanna, C., Stephenne, X., Revencu, N., Smets, F., Sassolas, A., Di Filippo, M., et al.
(2016). Homozygous familial hypercholesterolemia in childhood: genotype-
phenotype description, established therapies and perspectives. Atherosclerosis
247, 97–104. doi: 10.1016/j.atherosclerosis.2016.02.009
Saxon, D. R., and Eckel, R. H. (2016). Statin intolerance: a literature
review and management strategies. Prog. Cardiovasc. Dis. 59, 153–164.
doi: 10.1016/j.pcad.2016.07.009
Schettler, V. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Roeseler, E.,
et al. (2015). Impact of the German Lipoprotein Apheresis Registry (DLAR) on
therapeutic options to reduce increased Lp(a) levels. Clin. Res. Cardiol. Suppl.
10, 14–20. doi: 10.1007/s11789-015-0073-1
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J.,
Brumm, J., et al. (2012). Effects of dalcetrapib in patients with a recent acute
coronary syndrome. N. Engl. J. Med. 367, 2089–2099. doi: 10.1056/NEJMoa
1206797
Seftel, H. C., Baker, S. G., Jenkins, T., and Mendelsohn, D. (1989). Prevalence of
familial hypercholesterolemia in Johannesburg Jews. Am. J. Med. Genet. 34,
545–547. doi: 10.1002/ajmg.1320340418
Frontiers in Pharmacology | www.frontiersin.org 27 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
Seidah, N. G., Awan, Z., Chretien, M., and Mbikay, M. (2014). PCSK9:
a key modulator of cardiovascular health. Circ. Res. 114, 1022–1036.
doi: 10.1161/CIRCRESAHA.114.301621
Sharifi, M., Walus-Miarka, M., Idzior-Walus, B., Malecki, M. T., Sanak,
M., Whittall, R., et al. (2016). The genetic spectrum of familial
hypercholesterolemia in south-eastern Poland. Metab. Clin. Exp. 65, 48–53.
doi: 10.1016/j.metabol.2015.10.018
Sjouke, B., Kusters, D. M., Kindt, I., Besseling, J., Defesche, J. C., Sijbrands, E.
J., et al. (2015). Homozygous autosomal dominant hypercholesterolaemia in
the Netherlands: prevalence, genotype-phenotype relationship, and clinical
outcome. Eur. Heart J. 36, 560–565. doi: 10.1093/eurheartj/ehu058
Sjouke, B., Langslet, G., Ceska, R., Nicholls, S. J., Nissen, S. E., Ohlander, M., et al.
(2014). Eprotirome in patients with familial hypercholesterolaemia (the AKKA
trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet
Diabetes Endocrinol. 2, 455–463. doi: 10.1016/S2213-8587(14)70006-3
Sjouke, B., Yahya, R., Tanck, M. W. T., Defesche, J. C., de Graaf, J., Wiegman,
A., et al. (2017). Plasma lipoprotein(a) levels in patients with homozygous
autosomal dominant hypercholesterolemia. J. Clin. Lipidol. 11, 507–514.
doi: 10.1016/j.jacl.2017.02.010
Skoumas, J., Liontou, C., Chrysohoou, C., Masoura, C., Aznaouridis, K., Pitsavos,
C., et al. (2014). Statin therapy and risk of diabetes in patients with heterozygous
familial hypercholesterolemia or familial combined hyperlipidemia.
Atherosclerosis 237, 140–145. doi: 10.1016/j.atherosclerosis.2014.
08.047
Slimane, M. N., Pousse, H., Maatoug, F., Hammami, M., and Ben Farhat, M. H.
(1993). Phenotypic expression of familial hypercholesterolaemia in central and
southern Tunisia. Atherosclerosis 104, 153–158.
Smilde, T. J., van Wissen, S., Wollersheim, H., Trip, M. D., Kastelein, J. J.,
and Stalenhoef, A. F. (2001). Effect of aggressive versus conventional lipid
lowering on atherosclerosis progression in familial hypercholesterolaemia
(ASAP): a prospective, randomised, double-blind trial. Lancet 357, 577–581.
doi: 10.1016/S0140-6736(00)04053-8
Somanathan, S., Jacobs, F., Wang, Q., Hanlon, A. L., Wilson, J. M., and Rader, D.
J. (2014). AAV vectors expressing LDLR gain-of-function variants demonstrate
increased efficacy in mouse models of familial hypercholesterolemia. Circ. Res.
115, 591–599. doi: 10.1161/CIRCRESAHA.115.304008
Sonnett, T., Robinson, J., Milani, P., and Campbell, R. K. (2010). Role of
colesevelam in managing heterozygous familial hypercholesterolemia
in adolescents and children. Adolesc. Health Med. Ther. 1, 53–60.
doi: 10.2147/AHMT.S9272
Soslowsky, L. J., and Fryhofer, G. W. (2016). Tendon homeostasis
in hypercholesterolemia. Adv. Exp. Med. Biol. 920, 151–165.
doi: 10.1007/978-3-319-33943-614
Staels, B. (2009). A review of bile acid sequestrants: potential mechanism(s) for
glucose-lowering effects in type 2 diabetes mellitus. Postgrad. Med. 121, 25–30.
doi: 10.3810/pgm.2009.05.suppl53.290
Stefanutti, C., Morozzi, C., Di Giacomo, S., Sovrano, B., Mesce, D., and Grossi,
A. (2016). Management of homozygous familial hypercholesterolemia in
real-world clinical practice: a report of 7 Italian patients treated in Rome
with lomitapide and lipoprotein apheresis. J. Clin. Lipidol. 10, 782–789.
doi: 10.1016/j.jacl.2016.02.009
Stewart, A. (2013). SLCO1B1 polymorphisms and statin-induced myopathy. PLoS
Curr. 5. doi: 10.1371/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203
Steyn, K., Goldberg, Y. P., Kotze, M. J., Steyn, M., Swanepoel, A. S., Fourie, J. M.,
et al. (1996). Estimation of the prevalence of familial hypercholesterolaemia in
a rural Afrikaner community by direct screening for three Afrikaner founder
low density lipoprotein receptor gene mutations. Hum. Genet. 98, 479–484
Suda, T., and Liu, D. (2007). Hydrodynamic gene delivery: its principles
and applications. Mol. Ther. 15, 2063–2069. doi: 10.1038/sj.mt.
6300314
Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E.,
Shah, T., et al. (2015). HMG-coenzyme A reductase inhibition, type 2 diabetes,
and bodyweight: evidence from genetic analysis and randomised trials. Lancet
385, 351–361. doi: 10.1016/S0140-6736(14)61183-1
Tada, H., Kawashiri, M. A., Yoshida, T., Teramoto, R., Nohara, A., Konno, T.,
et al. (2016). Lipoprotein(a) in familial hypercholesterolemia with Proprotein
Convertase Subtilisin/Kexin Type 9 (PCSK9) gain-of-function mutations. Circ.
J. 80, 512–518. doi: 10.1253/circj.CJ-15-0999
Talmud, P. J., Shah, S., Whittall, R., Futema, M., Howard, P., Cooper, J. A., et al.
(2013). Use of low-density lipoprotein cholesterol gene score to distinguish
patients with polygenic and monogenic familial hypercholesterolaemia: a
case-control study. Lancet 381, 1293–1301. doi: 10.1016/S0140-6736(12)
62127-8
Tchernof, A., and Despres, J. P. (2013). Pathophysiology of human visceral obesity:
an update. Physiol. Rev. 93, 359–404. doi: 10.1152/physrev.00033.2011
Teichtahl, A. J., Brady, S. R., Urquhart, D. M., Wluka, A. E., Wang, Y., Shaw, J. E.,
et al. (2016). Statins and tendinopathy: a systematic review. Med. J. Aust. 204,
115.e111–121.e111. doi: 10.5694/mja15.00806
Thompson, G. R., Lowenthal, R., and Myant, N. B. (1975). Plasma exchange
in the management of homozygous familial hypercholesterolaemia. Lancet 1,
1208–1211.
Thompson, G. R., Miller, J. P., and Breslow, J. L. (1985). Improved survival of
patients with homozygous familial hypercholesterolaemia treated with plasma
exchange. Br. Med. J. (Clin. Res. Ed). 291, 1671–1673.
Tomaszewski, M., Stepien, K. M., Tomaszewska, J., and Czuczwar, S.
J. (2011). Statin-induced myopathies. Pharmacol. Rep. 63, 859–866.
doi: 10.1016/s1734-1140(11)70601-6
Torvik, K., Narverud, I., Ottestad, I., Svilaas, A., Gran, J. M., Retterstol, K.,
et al. (2016). Dietary counseling is associated with an improved lipid profile
in children with familial hypercholesterolemia. Atherosclerosis 252, 21–27.
doi: 10.1016/j.atherosclerosis.2016.07.913
Turgeon, R. D., Barry, A. R., and Pearson, G. J. (2016). Familial
hypercholesterolemia: review of diagnosis, screening, and treatment. Can.
Fam. Physician. 62, 32–37.
Turnbull, C., Scott, R. H., Thomas, E., Jones, L., Murugaesu, N., Pretty, F. B., et al.
(2018). The 100 000 Genomes Project: bringing whole genome sequencing to
the NHS. BMJ 361:k1687. doi: 10.1136/bmj.k1687
Turunen, T. A., Kurkipuro, J., Heikura, T., Vuorio, T., Hytonen, E., Izsvak, Z.,
et al. (2016). Sleeping beauty transposon vectors in liver-directed gene delivery
of LDLR and VLDLR for gene therapy of familial hypercholesterolemia. Mol.
Ther. 24, 620–635. doi: 10.1038/mt.2015.221
Tziomalos, K., Athyros, V. G., Karagiannis, A., and Mikhailidis, D. P. (2010).
Management of statin-intolerant high-risk patients. Curr. Vasc. Pharmacol. 8,
632–637. doi: 10.2174/157016110792006932
van Capelleveen, J. C., Kastelein, J. J., Zwinderman, A. H., van Deventer, S. J.,
Collins, H. L., Adelman, S. J., et al. (2016). Effects of the cholesteryl ester transfer
protein inhibitor, TA-8995, on cholesterol eﬄux capacity and high-density
lipoprotein particle subclasses. J. Clin. Lipidol. 10:1137.e1133–1144.e1133.
doi: 10.1016/j.jacl.2016.06.006
van denOord, S. C., Akkus, Z., Roeters van Lennep, J. E., Bosch, J. G., van der Steen,
A. F., Sijbrands, E. J., et al. (2013). Assessment of subclinical atherosclerosis
and intraplaque neovascularization using quantitative contrast-enhanced
ultrasound in patients with familial hypercholesterolemia. Atherosclerosis 231,
107–113. doi: 10.1016/j.atherosclerosis.2013.08.040
Van Horn, L. (1997). Fiber, lipids, and coronary heart disease. A statement
for healthcare professionals from the Nutrition Committee, American Heart
Association. Circulation 95, 2701–2704. doi: 10.1161/01.CIR.95.12.2701
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C.,
Liem, A. H., et al. (2008). Efficacy of statins in familial hypercholesterolaemia:
a long term cohort study. BMJ 337:a2423. doi: 10.1136/bmj.a2423
Vetrini, F., and Ng, P. (2010). Gene therapy with helper-dependent adenoviral
vectors: current advances and future perspectives. Viruses 2, 1886–1917.
doi: 10.3390/v2091886
Vickery, A. W., Bell, D., Garton-Smith, J., Kirke, A. B., Pang, J., and
Watts, G. F. (2014). Optimising the detection and management of
familial hypercholesterolaemia: central role of primary care and its
integration with specialist services. Heart Lung Circ. 23, 1158–1164.
doi: 10.1016/j.hlc.2014.07.062
Villa, G., Wong, B., Kutikova, L., Ray, K. K., Mata, P., and Bruckert,
E. (2017). Prediction of cardiovascular risk in patients with familial
hypercholesterolaemia. Eur Heart J. Qual. Care Clin. Outcomes 3, 274–280.
doi: 10.1093/ehjqcco/qcx011
Villicev, C. M., Freitas, F. R., Aoki, M. S., Taffarel, C., Scanlan, T. S., Moriscot, A.
S., et al. (2007). Thyroid hormone receptor beta-specific agonist GC-1 increases
energy expenditure and prevents fat-mass accumulation in rats. J. Endocrinol.
193, 21–29. doi: 10.1677/joe.1.07066
Frontiers in Pharmacology | www.frontiersin.org 28 July 2018 | Volume 9 | Article 707
Mytilinaiou et al. FH: Diagnosis and Management
Visser, M. E., Akdim, F., Tribble, D. L., Nederveen, A. J., Kwoh, T. J., Kastelein,
J. J., et al. (2010). Effect of apolipoprotein-B synthesis inhibition on liver
triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res.
51, 1057–1062. doi: 10.1194/jlr.M002915
Vuorio, A. F., Turtola, H., Piilahti, K. M., Repo, P., Kanninen, T., and Kontula,
K. (1997). Familial hypercholesterolemia in the Finnish north Karelia. A
molecular, clinical, and genealogical study. Arterioscler. Thromb. Vasc. Biol. 17,
3127–3138.
Walldius, G., and Jungner, I. (2004). Apolipoprotein B and apolipoprotein
A-I: risk indicators of coronary heart disease and targets for lipid-
modifying therapy. J. Intern.Med. 255, 188–205. doi: 10.1046/j.1365-2796.2003.
01276.x
Walsh, M. T., and Hussain, M. M. (2016). Targeting microsomal triglyceride
transfer protein and lipoprotein assembly to treat homozygous
familial hypercholesterolemia. Crit. Rev. Clin. Lab Sci. 54, 26–48.
doi: 10.1080/10408363.2016.1221883
Walus-Miarka, M., Czarnecka, D., Wojciechowska, W., Kloch-Badelek,
M., Kapusta, M., Sanak, M., et al. (2016). Carotid plaques correlates
in patients with familial hypercholesterolemia. Angiology 67, 471–477.
doi: 10.1177/0003319715596281
Wang, X., Li, W., Hao, L., Xie, H., Hao, C., Liu, C., et al. (2018). The therapeutic
potential of CETP inhibitors: a patent review. Expert Opin. Ther. Pat. 28,
331–340. doi: 10.1080/13543776.2018.1439476
Watts, G. F., Gidding, S., Wierzbicki, A. S., Toth, P. P., Alonso, R., Brown, W. V.,
et al. (2015). Integrated guidance on the care of familial hypercholesterolaemia
from the International FH Foundation. Eur. J. Prev. Cardiol. 22, 849–854.
doi: 10.1177/2047487314533218
Wiegman, A., Gidding, S. S.,Watts, G. F., Chapman,M. J., Ginsberg, H. N., Cuchel,
M., et al. (2015). Familial hypercholesterolaemia in children and adolescents:
gaining decades of life by optimizing detection and treatment. Eur. Heart J. 36,
2425–2437. doi: 10.1093/eurheartj/ehv157
Wiggins, B. S., Senfield, J., Kassahun, H., Lira, A., and Somaratne, R. (2018).
Evolocumab: considerations for the management of hyperlipidemia. Curr.
Atheroscler. Rep. 20:17. doi: 10.1007/s11883-018-0720-3
Writing, C., Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher,
K. K., Daly, D. D. Jr., et al. (2016). 2016 ACC expert consensus decision
pathway on the role of non-statin therapies for LDL-cholesterol lowering in
the management of atherosclerotic cardiovascular disease risk: a report of
the American college of cardiology task force on clinical expert consensus
documents. J. Am. Coll. Cardiol. 68, 92–125. doi: 10.1016/j.jacc.2016.03.519
Yoo, E. G. (2016). Sitosterolemia: a review and update of pathophysiology, clinical
spectrum, diagnosis, and management. Ann. Pediatr. Endocrinol. Metab. 21,
7–14. doi: 10.6065/apem.2016.21.1.7
Zamora, A., Masana, L., Comas-Cufi, M., Vila, A., Plana, N., Garcia-Gil, M.,
et al. (2017). Familial hypercholesterolemia in a European Mediterranean
population-prevalence and clinical data from 2.5 million primary care patients.
J. Clin. Lipidol. 11, 1013–1022. doi: 10.1016/j.jacl.2017.05.012
Zani, I. A., Stephen, S. L., Mughal, N. A., Russell, D., Homer-Vanniasinkam, S.,
Wheatcroft, S. B., et al. (2015). Scavenger receptor structure and function in
health and disease. Cells 4, 178–201. doi: 10.3390/cells4020178
Zheng, K. H., van der Valk, F. M., Smits, L. P., Sandberg, M., Dasseux,
J. L., Baron, R., et al. (2016). HDL mimetic CER-001 targets
atherosclerotic plaques in patients. Atherosclerosis 251, 381–388.
doi: 10.1016/j.atherosclerosis.2016.05.038
Zhou, M., and Zhao, D. (2016). Familial hypercholesterolemia in Asian
populations. J. Atheroscler. Thromb. 23, 539–549. doi: 10.5551/jat.34405
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Mytilinaiou, Kyrou, Khan, Grammatopoulos and Randeva. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 29 July 2018 | Volume 9 | Article 707
